Uvithamini K

-Delile

• Iyasebenza ku ...
• Kungenzeka kusebenze ...
• Kungenzeka kungasebenzi ku ...
• Ubufakazi obanele bokukala ukusebenza kwe ...
• Ukuqapha okukhethekile nezixwayiso:

UVitamin K uvithamini otholakala emifino eluhlaza, ama-broccoli namahlumela aseBrussels. Igama uvithamini K livela egameni lesiJalimane elithi "Koagulationsvitamin."

Izinhlobo eziningi zikavithamini K zisetshenziswa emhlabeni wonke njengomuthi. UVitamin K1 (phytonadione) novithamini K2 (menaquinone) ayatholakala eNyakatho Melika. IVitamin K1 imvamisa iyindlela ethandwayo kavithamini K ngoba ayinabuthi kangako futhi isebenza ngokushesha ezimeni ezithile.

UVitamin K uvame ukusetshenziselwa izinkinga zokuvala igazi noma ukuguqula imiphumela emibi yegazi ye-warfarin.Isetshenziselwa nezinye izimo eziningi, kepha abukho ubufakazi obuhle besayensi bokuxhasa okuningi kwalokhu okunye ukusetshenziswa.

Imibhalo Yemvelo Yemininingwane Ephelele ukukala ukusebenza ngokuncike ebufakazini besayensi ngokwesilinganiso esilandelayo: Okusebenzayo, Okungenzeka Kusebenze, Okungenzeka Kusebenze, Okungenzeka Kungasebenzi, Cishe Okungaphumeleli, Ukungasebenzi, Nobufakazi Obunganele Bokulinganisa.

Izilinganiso zokusebenza ze IVITAMIN K zimi kanje:

Iyasebenza ku ...

• Izinkinga zokopha ezinganeni ezisanda kuzalwa ezinamazinga aphansi kavithamini K (isifo sokopha). Ukunikeza i-vitamin K1 ngomlomo noma njengesibhamu emisipheni kusiza ukuvimbela izinkinga zokopha ezinganeni ezisanda kuzalwa. Ama-Shots abonakala esebenza kahle kakhulu.
• Amazinga aphansi we-protein clotting prothrombin (hypoprothrombinemia). Ukuthatha i-vitamin K1 ngomlomo noma njengomjovo emthanjeni kungavimbela futhi kuphathe izinkinga zokopha kubantu abanamazinga aphansi e-prothrombin ngenxa yokusebenzisa imishanguzo ethile.
• Isifo esingajwayelekile, esizuza njengefa (ukuntuleka kwamavithamini K ancike ezintweni noma ama-VKCFD). Ukuthatha i-vitamin K ngomlomo noma njengomjovo emthanjeni kungasiza ekuvimbeleni ukopha kubantu abane-VKCFD.
• Ukuguqula imiphumela yokuncipha kwegazi kwe-warfarin. Ukuthatha i-vitamin K1 ngomlomo noma njengokujova emthanjeni kungaguqula ukuncipha kwegazi okuningi okubangelwa yi-warfarin. Kodwa-ke, ukujova i-vitamin K1 ngaphansi kwesikhumba kubonakala kungasebenzi. Ukuthatha i-vitamin K kanye ne-warfarin nakho kubonakala kusiza ekuqiniseni isikhathi sokuvala igazi kubantu abathatha i-warfarin. Isebenza kahle kubantu abanamazinga aphansi kavithamini K.

Kungenzeka kusebenze ...

• Amathambo abuthakathaka futhi anamandla (i-osteoporosis). Ukuthatha uhlobo oluthile lwevithamini K2 kubonakala kuthuthukisa amandla amathambo futhi kunciphisa ubungozi bokuqhekeka kwabesifazane abaningi asebekhulile abanamathambo abuthaka. Kodwa akubonakali kuzuzisa abesifazane asebekhulile abasenamathambo aqinile. Ukuthatha i-vitamin K1 kubonakala kukhulisa amandla amathambo futhi kungavimbela ukuphuka kwabesifazane asebekhulile. Kepha kungahle kungasebenzi kahle emadodeni amadala. I-Vitamin K1 ibonakala ingathuthukisi amandla amathambo kwabesifazane abangazange badlule esikhathini sokuya esikhathini noma kubantu abanesifo seCrohn.

Kungenzeka kungasebenzi ku ...

• Ukopha ngaphakathi noma ezungeze izindawo ezigcwele uketshezi (ama-ventricles) obuchopho (ukopha ngaphakathi). Ukunikeza abantu besifazane abasengozini yokuzalwa ngaphambi kokubeletha kubonakala kungavimbi ukopha ebuchosheni bezinsana ezizalwe ngaphambi kwesikhathi. Futhi akubonakali kunciphisa ubungozi bokulimala kwemizwa okubangelwa yilokhu kuphuma kwegazi.

Ubufakazi obanele bokukala ukusebenza kwe ...

• Ukusebenza kwezemidlalo. Ucwaningo lwakuqala luphakamisa ukuthi ukuthatha i-vitamin K2 ngomlomo kungathuthukisa ukusebenza kokuvivinya umzimba ngokwandisa umsebenzi wenhliziyo.
• Isifo segazi esinciphisa amazinga wamaprotheni egazini okuthiwa i-hemoglobin (beta-thalassemia). Ucwaningo lokuqala lubonisa ukuthi ukuthatha i-vitamin K2 ngomlomo kanye ne-calcium ne-vitamin D kungathuthukisa ithambo ezinganeni ezinalesi sifo segazi.
• Umdlavuza webele. Ucwaningo luphakamisa ukuthi ukudla okunomsoco ophezulu wevithamini K2 kuhlotshaniswa nengozi ephansi yokuthola umdlavuza webele.
• Umdlavuza. Olunye ucwaningo luxhumanise ukudla okuphezulu kukavithamini K2, kepha hhayi uvithamini K1, nengozi encishisiwe yokufa ngenxa yomdlavuza. Kodwa olunye ucwaningo luxhumanise ukudla okuphezulu kukavithamini K1, kepha hhayi uvithamini K2, nengozi encishisiwe yokufa ngenxa yomdlavuza.
• Isifo senkwethu. Olunye ucwaningo luxhumanise ukudla okuphezulu kwe-vitamin K2 ngengozi ephansi yokuthola i-cataract.
• Umdlavuza wamakholoni, umdlavuza we-rectal. Ucwaningo lwakuqala luphakamisa ukuthi ukudla okunomsoco ophakeme kavithamini K akuxhunyaniswa nengozi encishisiwe yomdlavuza wekoloni kanye nengxenyeni.
• Isifo senhliziyo. Iningi locwaningo lukhombisa ukuthi ukudla okuphezulu kokudla i-vitamin K1 ne-K2 kuhlotshaniswa nokwehla kwengozi yesifo senhliziyo. Kodwa ukudla okuphezulu kwe-vitamin K1 kubonakala kunganciphisi ingozi yokufa ngesifo senhliziyo ngokujwayelekile.
• ICystic fibrosis. Abantu abane-cystic fibrosis banamazinga aphansi kavithamini K ngenxa yezinkinga zokugaya amafutha. Ukuthatha uvithamini K kwandisa amazinga kavithamini K. Kepha akucaci noma ngabe kuvimbela izinkinga zokuqina kwegazi nokukhula kwethambo kulaba bantu.
• Ukucindezeleka. Ucwaningo lwakuqala luthole ukuthi ukudla okuphezulu kwe-vitamin K ekudleni kuxhumene nengozi ephansi yokudangala. Kodwa alukho ucwaningo lokuthi ukuthatha izithasiselo zikavithamini K kungayinciphisa yini ingozi yokudangala.
• Isifo sikashukela. Ucwaningo lwakuqala lukhombisa ukuthi ukuthatha i-multivitamin eqiniswe ngovithamini K1 akwehlisi ingozi yokuba nesifo sikashukela uma kuqhathaniswa nokuthatha i-multivitamin ejwayelekile.
• Ukuqubuka okufana nezinduna okubangelwa yimithi ethile yomdlavuza. Abantu abanikezwa uhlobo oluthile lomuthi we-anticancer bavame ukuba nokuqubuka kwesikhumba. Ucwaningo lwakuqala lukhombisa ukuthi ukufaka ukhilimu oqukethe uvithamini K1 kusiza ukuvimbela ukuqubuka kwesikhumba kubantu abanikezwa lolu hlobo lomuthi. Kepha olunye ucwaningo lukhombisa ukuthi ukusebenzisa umuthi onamavithamini K akukuthuthukisi lokhu kuqubuka kubantu asebevele bakwenzile.
• I-cholesterol ephezulu. Kunobufakazi bokuqala bokuthi i-vitamin K2 ingehlisa i-cholesterol kubantu abaku-dialysis ngamazinga aphezulu we-cholesterol.
• Umdlavuza wesibindi. Ukuthatha i-vitamin K2 kubonakala kungavimbi ukuphindaphinda komdlavuza wesibindi. Kepha olunye ucwaningo lwakuqala lukhombisa ukuthi ukuthatha i-vitamin K2 kunciphisa ubungozi bomdlavuza wesibindi kubantu abane-cirrhosis yesibindi.
• Isifo sesibindi. Ukujova i-vitamin K emisipheni kuye kwaxhunyaniswa nengozi ephansi yokufa kubantu abanesibindi sokuhluleka.
• Umdlavuza wamaphaphu. Ucwaningo lwakuqala luphakamisa ukuthi ukudla okuphezulu kwe-vitamin K2 ekudleni kuhlotshaniswa nengozi encishisiwe yomdlavuza wamaphaphu nokufa okuhlobene nomdlavuza wamaphaphu. Ukudla i-vitamin K1 kubonakala kungahlobene nengozi encishisiwe yale micimbi.
• I-Multiple sclerosis (MS). I-Interferon ngumuthi osiza abantu abane-MS. Lo muthi uvame ukudala ukuqubuka nokushisa kwesikhumba. Ucwaningo lwakuqala lukhombisa ukuthi ukusebenzisa ukhilimu kavithamini K kunciphisa ukuqubuka nokushisa kubantu abaphathwe nge-interferon.
• Ukufa nganoma yisiphi isizathu. Ukudla okuphansi kuka-vitamin K kungahle kuxhunyaniswe nengozi enkulu yokufa kubantu abadala asebekhulile.
• Umdlavuza wendlala yesinye. Ucwaningo lwakuqala luthole ukuthi ukudla okunomsoco ophakeme wevithamini K2, kepha hhayi uvithamini K1, kuxhunyaniswa nokwehla kwengozi yomdlavuza wesinye.
• Isifo samathambo (RA). Ucwaningo lwakuqala lukhombisa ukuthi ukuthatha uvithamini K2 kanye nomuthi wesifo samathambo kunciphisa izimpawu zokuvuvukala okuhlangene kangcono kunokuphuza umuthi wesifo samathambo uwedwa. Kepha ukuthatha i-vitamin K1 kubonakala kunganciphisi izimpawu ze-RA.
• Unhlangothi. Ucwaningo lwabantu luthole ukuthi ukudla okunomsoco wevithamini K1 akuxhunyaniswa nokwehla kwengozi yokushaywa unhlangothi.
• Imivimbo.
• Kushe.
• Izibazi.
• Imithambo yesicabucabu.
• Amamaki wokunweba.
• Ukuvuvukala.
• Ezinye izimo.

Kudingeka ubufakazi obengeziwe ukukala uvithamini K walokhu kusetshenziswa.

UVitamin K uvithamini obalulekile odingeka emzimbeni ekunqandeni igazi, ekwakheni amathambo, nakwezinye izinqubo ezibalulekile.

Lapho ithathwa ngomlomo: Izinhlobo ezimbili zikavithamini K (uvithamini K1 novithamini K2) ZIPHEPHILE kubantu abaningi uma zithathwe ngendlela efanele. Uvithamini K1 10 mg nsuku zonke novithamini K2 45 mg nsuku zonke kusetshenziswe ngokuphepha kuze kube yiminyaka emibili. Iningi labantu alinayo imiphumela emibi lapho lithatha uvithamini K kunani elinconyiwe usuku ngalunye. Kepha abanye abantu bangaba nesisu noma uhudo.

Lapho isetshenziswa esikhunjeni: Uvithamini K1 unjalo OKUNGENZEKA UKUPHEPHA kubantu abaningi lapho isetshenziswa njengokhilimu oqukethe u-0.1% uvithamini K1.

Uma unikezwa yi-IV: Izinhlobo ezimbili zikavithamini K (uvithamini K1 novithamini K2) yilezi CISHE UVIKILE kubantu abaningi lapho bejojowe emthanjeni ngokufanele.

Ukuqapha okukhethekile nezixwayiso:

Ukukhulelwa nokuncelisa ibele: Uma ithathwa ngenani elinconyiwe usuku ngalunye, uvithamini K ngu CISHE UVIKILE kwabesifazane abakhulelwe nabancelisa ibele. Ungasebenzisi amanani aphakeme ngaphandle kweseluleko sikachwepheshe wezokunakekelwa kwezempilo.

Izingane: Uhlobo lwevithamini K olwaziwa ngevithamini K1 ngu CISHE UVIKILE ezinganeni lapho zithathwa ngomlomo noma zifakwa emzimbeni ngokufanele.

Isifo sezinso: Uvithamini K omningi kakhulu angaba yingozi uma uthola ukwelashwa nge-dialysis ngenxa yesifo sezinso.

Isifo sesibindi: Uvithamini K awusebenzi ekwelapheni izinkinga zokujiyisana ezibangelwa yisifo esibi sesibindi. Eqinisweni, amanani aphakeme kavithamini K angenza izinkinga zokujiya zibe zimbi kakhulu kulaba bantu.

Ukwehlisa uketshezi lwe-bile: Abantu abanciphise uketshezi lwe-bile abathatha uvithamini K kungenzeka badinge ukuthatha osawoti bengeziwe be-bile kanye novithamini K ukuqinisekisa ukumuncwa kukavithamini K.

Okukhulu

Ungathathi le nhlanganisela.

I-Warfarin (Coumadin)

UVitamin K usetshenziswa ngumzimba ukusiza ukunqamuka kwegazi. I-Warfarin (i-Coumadin) isetshenziselwa ukunciphisa ukubamba kwegazi. Ngokusiza i-clot yegazi, i-vitamin K inganciphisa ukusebenza kwe-warfarin. Qiniseka ukuthi uhlolwa igazi lakho njalo. Umthamo we-warfarin yakho ungadinga ukuguqulwa.

ICoenzyme Q10

ICoenzyme Q10 ifana ngokwamakhemikhali novithamini K futhi, njengevithamini K, ingakhuthaza ukujiya kwegazi. Ukusebenzisa le mikhiqizo emibili ndawonye kungakhuthaza ukujiya kwegazi ngaphezu kokusebenzisa owodwa. Le nhlanganisela ingaba yinkinga kubantu abathatha i-warfarin ukunciphisa ijubane lokuvala igazi. ICoenzyme Q10 kanye novithamini K angahle akhungathekise imiphumela ye-warfarin futhi angavumela igazi ukuba lijiye.

I-Tiratricol

Kukhona ukukhathazeka ngokuthi i-tiratricol ingaphazamisa indima ka-vitamin K ekunqandeni igazi.

Uvithamini A

Ezilwaneni, amanani aphezulu kavithamini A aphazamisa ikhono likavithamini K lokuvala igazi. Kodwa akwaziwa ukuthi lokhu kuyenzeka nasebantwini.

Uvithamini E

Ukweqiwa okuphezulu kukavithamini E (isb.ngaphezulu kwamayunithi angu-800 / ngosuku) kungenza uvithamini K angasebenzi kahle ekuvaleni igazi. Kubantu abathatha i-warfarin ukugcina igazi labo lingaqandi, noma kubantu abathola u-vitamin K ophansi, imithamo ephezulu ka-vitamin E ingakhuphula ubungozi bokuphuma kwegazi.

Amafutha nokudla okuqukethe amafutha

Ukudla ukudla okuqukethe ibhotela noma amanye amafutha okudla kuhlanganiswe nokudla okuqukethe u-vitamin K, njengesipinashi, kubonakala kukhulisa ukumuncwa kukavithamini K.

Imithamo elandelayo ifundwe ocwaningweni lwesayensi:

ABADALA

NGOMLOMO:

• Amathambo abuthakathaka futhi aphuke (i-osteoporosis): Ifomu le-MK-4 likavithamini K2 lithathwe ngemithamo ka-45 mg nsuku zonke. Futhi, i-vitamin K1 ithathwe ngemithamo ye-1-10 mg nsuku zonke.
• Ngesifo esingajwayelekile, esizuza njengefa (ukungabi namandla kwe-vitamin K noma i-VKCFD): 10 mg kavithamini K uphuzwe izikhathi ezingama-2-3 masonto onke.
• Ngokuhlehlisa imiphumela yokuncipha kwegazi ye-warfarin: Umthamo owodwa ka-1-5 mg kavithamini K1 uvame ukusetshenziselwa ukubuyisa imiphumela yokuthatha i-warfarin eningi kakhulu. Umthamo oqondile odingekayo unqunywa ukuhlolwa kwelebhu okuthiwa i-INR. Imithamo yansuku zonke yama-micrograms ayi-100-200 kavithamini K isetshenziselwe abantu abathatha i-warfarin yesikhathi eside abanokuqina kwegazi okungazinzile.

NGENALITHI:

• Ngesifo esingajwayelekile, esivela egazini (ukwelekelela kwe-vitamin K noma i-VKCFD): 10 mg kavithamini K ufakiwe emthanjeni. Ukuthi lemijovo inikezwa kaningi kangakanani kunqunywa ukuhlolwa kwelebhu okuthiwa i-INR.
• Ngokuhlehlisa imiphumela yokuncipha kwegazi ye-warfarin: Umthamo owodwa ka-0.5-3 mg kavithamini K1 uvame ukusetshenziswa. Umthamo oqondile odingekayo unqunywa ukuhlolwa kwelebhu okuthiwa i-INR.

IZINGANE

NGOMLOMO:

• Ngezinkinga zokopha ezinganeni ezisanda kuzalwa ezinamazinga aphansi kavithamini K (isifo esopha): 1-2 mg wevithamini K1 unikezwe ngemithamo emithathu emavikini ayisishiyagalombili. Kusetshenziswe nemithamo eyodwa equkethe u-1 mg kavithamini K1, 5 mg kavithamini K2, noma u-1-2 mg kavithamini K3.

NGENALITHI:

• Ngezinkinga zokopha ezinganeni ezisanda kuzalwa ezinamazinga aphansi kavithamini K (isifo esopha)I-1 mg yevithamini K1 inikezwe njengesibhamu emisipheni.

Alukho ulwazi olwanele lwesayensi lokunquma izibonelelo zokudla ezinconyiwe (ama-RDA) kavithamini K, ngakho-ke kusetshenziswa izincomo zansuku zonke zokudla okwanele (AI) esikhundleni: Ama-AI yilezi: izinsana izinyanga ezingama-0-6, 2 mcg; izinsana izinyanga ezingu-7-12, 2.5 mcg; izingane ezineminyaka engu-1-3, 30 mcg; izingane ezineminyaka engu-4-8, i-55 mcg; izingane iminyaka 9-13, 60 mcg; intsha eneminyaka eyi-14-18 (kufaka phakathi labo abakhulelwe noma abancelisa ibele), i-75 mcg; amadoda angaphezu kweminyaka engu-19, 120 mcg; abesifazane abaneminyaka engaphezu kwengu-19 (kufaka phakathi labo abakhulelwe nabancelisa ibele), 90 mcg.

I-2-methyl-1,4-naphthoquinone, 2-methyl-3-phytyl-1,4-naphthoquinone, 4-Amino-2-Methyl-1-Naphthol, Vitamin-Soluble Vitamin, Menadiol, Menadiol Acetate, Menadiol Diacetate, Menadiol Sodium Diphosphate, Menadiol Sodium Phosphate, Menadiolum Solubile Methynaphthohydroquinone, Menadione, Ménadione, Menadione Sodium Bisulfite, Menaquinone, Ménaquinone, Menatetrenone, Menatétrenone, Phytonadione, Methylphytyl Naphtylosone, Phylonylone, Phylonone .

Ukuze ufunde kabanzi ngokuthi le ndatshana ibhalwe kanjani, sicela ubheke ifayela le- Imibhalo Yemvelo Yemininingwane Ephelele indlela.

1. U-Xiong Z, uLiu Y, u-Chang T, et al. Umphumela kavithamini K1 ekusindeni kweziguli ezinokwehluleka kwesibindi okungapheli: Ucwaningo lweqembu eliphindayo. Imithi (iBaltimore). 2020; 99: e19619. Buka okungaqondakali.
2. UTurck D, uBresson JL, uBurlingame B, et al. Amanani esithenjwa sokudla wevithamini K. EFSA J. 2017; 15: e04780. Buka okungaqondakali.
3. UShea MK, uBarger K, uBooth SL, et al. Isimo se-Vitamin K, isifo senhliziyo nemithambo yegazi, kanye nokufa konke okudala imbangela: ukuhlaziywa kwamamitha angama-3 aseMelika. Ngingu-J J Nutriti Womtholampilo. 2020; 111: 1170-1177. Buka okungaqondakali.
4. Kuang X, Liu C, Guo X, Li K, Deng Q, Li D. Umphumela wokuhlanganiswa kukavithamini K novithamini D kukhwalithi yamathambo womuntu: ukuhlaziywa kwemeta kwezilingo ezilawulwa ngokungahleliwe. Umsebenzi Wokudla. 2020; 11: 3280-3297. Buka okungaqondakali.
5. UJagannath VA, Thaker V, Chang AB, Intengo ye-AI. Ukwengeza i-Vitamin K ye-cystic fibrosis. ICochrane Database Syst Rev. 2020; 6: CD008482. Buka okungaqondakali.
6. UHashimoto H, Iwasa S, Yanai-Takahashi T, et al. Isigaba Esilawulwa Ngokungahleliwe, Esingaboni Ngamehlo, Esilawulwa Nge-Placebo? Fundisisa ngokuSebenza nokuPhepha kwamaVithamini K1 wamafutha weCetuximab noma iPanitumumab-Induced Acneiform Eruptions-VIKTORIA Study. Ukuya kuKagaku Ryoho. 2020; 47: 933-939. Buka okungaqondakali.
7. UMott A, uBradley T, uWight K, et al. Umphumela kavithamini K ekucineni kwamaminerali amathambo kanye nokwaphuka kwabantu abadala: ukubuyekezwa okuhlelekile okuhlelekile nokuhlaziywa kwemeta kokuhlolwa okulawulwa ngokungahleliwe. I-Osteoporos Int 2019; 30: 1543-59. i-doi: 10.1007 / s00198-019-04949-0. Buka okungaqondakali.
8. UChen HG, uSheng LT, uZhang YB, et al. Inhlangano kavithamini K enemicimbi yenhliziyo nemithambo yegazi kanye nayo yonke imbangela yokufa: ukubuyekezwa okuhlelekile nokuhlaziywa kwemeta. I-Eur J Umsoco 2019; 58: 2191-205. i-doi: 10.1007 / s00394-019-01998-3. Buka okungaqondakali.
9. U-Oikonomaki T, uPapasotiriou M, uNtrinias T, et al. Umphumela we-vitamin K2 supplementation ekubalweni kwamathambo ezigulini ze-hemodialysis: isilingo esilandelwayo sokulandela unyaka esingu-1. I-Int Urol Nephrol 2019; 51: 2037-44. i-doi: 10.1007 / s11255-019-02275-2. Buka okungaqondakali.
10. ULöwensteyn YN, uJansen NJG, van Heerde M, et al. Ukwandisa umthamo we-vitamin K prophylaxis yomlomo nomphumela wayo engcupheni yokopha. I-Eur J Pediatr 2019; 178: 1033-42. i-doi: 10.1007 / s00431-019-03391-y. Buka okungaqondakali.
11. UShishavan NG, Gargari BP, Jafarabadi MA, Kolahi S, Haggifar S, Noroozi S. Vitamin K ukwengeza akuzange kuguqule izimpawu zokuvuvukala kanye nesimo somtholampilo ezigulini ezinesifo samathambo. I-Int J Vitam Nutr Res. I-2018; 88 (5-6): 251-257. Buka okungaqondakali.
12. UBolzetta F, uVeronese N, uStubbs B, et al. Ubudlelwano phakathi kokudla okunamavithamini K nezimpawu zokudangala ekukhuleni sekwedlule isikhathi: Ukuhlaziywa kwesigaba esiphambanweni kusuka ocwaningweni olukhulu lweqembu. Izakhamzimba. 2019; 11. pii: E787. Buka okungaqondakali.
13. UMcFarlin BK, uHenning AL, uVenable AS. Ukusetshenziswa ngomlomo kukavithamini K2 amasonto ayi-8 ahlobene nokukhishwa kwenhliziyo okukhulu ngesikhathi sokuzivocavoca. I-Altern Ther Health Med. 2017; 23: 26-32. Buka okungaqondakali.
14. UCamacho-Barcia ML, uBulló M, uGarcia-Gavilán JF, et al. Inhlangano yokudla i-vithamini K1 yokudla kanye nesigameko sokuhlinzwa kwe-cataract kubantu abadala baseMedithera: ukuhlaziywa kwesibili kwesilingo somtholampilo esingahleliwe. JAMA Ophthalmol. 2017; 135: 657-61. Buka okungaqondakali.
15. UHolbrook A, uSchulman S, uWitt DM, et al. Ukuphathwa okususelwe ebufakazini bokwelashwa kwe-anticoagulant: Therapy Antithrombotic and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Guid-based Clinical Practice Guidelines. Isifuba 2012; 141: e152S-e184S. Buka okungaqondakali.
16. Ozdemir MA, Yilmaz K, Abdulrezzak U, Muhtaroglu S, Patiroglu T, Karakukcu M, Unal E. Ukusebenza kahle kwe-vitamin K2 kanye nenhlanganisela ye-calcitriol kwi-thalassemic osteopathy. UJ Pediatr Hematol Oncol. 2013; 35: 623-7. Buka okungaqondakali.
17. UPinta F, uPonzetti A, uSpadi R, uFanchini L, uZanini M, uMecca C, uSonetto C, uCiuffreda L, uRacca P. Isilingo somtholampilo mayelana nokusebenza kahle kwephylactic yokusetshenziswa kokhilimu osuselwa ku-vitamin K1 (Vigorskin) ukuvimbela ukwenziwa kwe-cetuximab ukuqubuka kwesikhumba ezigulini ezinomdlavuza we-metastatic colorectal. Umdlavuza Wasemtholampilo. 2014; 13: 62-7. Buka okungaqondakali.
18. U-O'Connor EM, uGrealy G, uMcCarthy J, uDesmond A, uCraig O, uShanahan F, uCashman KD. Umphumela we-phylloquinone (vitamin K1) yokwengeza izinyanga eziyi-12 kuma-indices wesimo sevithamini K nempilo yamathambo ezigulini zabantu abadala abanesifo sikaCrohn. UBr J Nutriti. 2014; 112: 1163-74. Buka okungaqondakali.
19. Lanzillo R, Moccia M, Carotenuto A, Vacchiano V, Satelliti B, Panetta V, Brescia Morra V. Vitamin K ukhilimu kunciphisa ukusabela esizeni somjovo ezigulini ezinesifo sokuqina kwamathishu esibuyisanayo eselashwa nge-subcutaneous interferon beta - Ucwaningo lweVIKING. I-Mult Scler. 2015; 21: 1215-6. Buka okungaqondakali.
20. UJuanola-Falgarona M, Salas-Salvadó J, Martínez-González MÁ, Corella D, Estruch R, Ros E, Fitó M, Arós F, Gómez-Gracia E, Fiol M, Lapetra J, Basora J, Lamuela-Raventós RM, Serra -Majem L, Pintó X, Muñoz MÁ, Ruiz-Gutiérrez V, Fernández-Ballart J, Bulló M.Ukudla kwe-vitamin K kuhlotshaniswa nobungozi bokufa kwabantu. J Umsoco. 2014; 144: 743-50. Buka okungaqondakali.
21. I-Huang ZB, i-Wan SL, i-Lu YJ, i-Ning L, i-Liu C, i-Fan SW. Ngabe i-vitamin K2 ibamba iqhaza ekuvimbeleni nasekwelapheni i-osteoporosis yabesifazane be-postmenopausal: ukuhlaziywa kwe-meta-kwezivivinyo ezilawulwa ngokungahleliwe. Osteoporos Int. 2015; 26: 1175-86. Buka okungaqondakali.
22. UCaluwé R, uVandecasteele S, uVan Vlem B, uVermeer C, uDe Vriese AS. Ukwengeza i-Vitamin K2 ezigulini ze-hemodialysis: isifundo esingahleliwe sokuthola umthamo. Ukufakelwa kabusha kweNephrol Dial. 2014; 29: 1385-90. Buka okungaqondakali.
23. U-Abdel-Rahman MS, Alkady EA, Ahmed S. Menaquinone-7 njengokwelashwa kwemithi yokwelapha ekwelapheni i-rheumatoid arthritis: Isifundo somtholampilo. I-Eur J Pharmacol. 2015; 761: 273-8. Buka okungaqondakali.
24. I-Dennis VC, i-Ripley TL, i-Planas LG, ne-Beach P. I-vitamin K yokudla ezigulini zomlomo zokulwa ne-anticoagulation: imikhuba yokwelashwa kanye nolwazi kuzilungiselelo zabangalaliswayo. UJ Pharm Technol. 2008; 24: 69-76.
25. UPathak A, uHamm CR, u-Eyal FG, uWalter K, uRijhsinghani A, noBohlman M. Ukuphathwa kukavithamini K womama wokuvikela ukopha okungaphakathi emithanjeni ezinganeni ezizalwe ngaphambi kwesikhathi. Ucwaningo lwezingane 1990; 27: 219A.
26. I-Eisai Co. Ltd. I-Eisai imemezela ukuhlaziywa okuphakathi kocwaningo lokwelashwa kwamathambo ngemuva kokumaketha ukuphenya ngezinzuzo ze-menatetrenone njengengxenye yohlelo loMnyango Wezempilo, Ezabasebenzi kanye Nezenhlalakahle lweFarmacoepidemiological Drug Review Programme. 2005;
27. Imiphumela ye-Shiraki M. Vitamin K2 engcupheni yokuqhekeka nasesixungeni samathambo amaminerali ku-osteoporosis - isifundo esingahleliwe selebuli evulelekile yeminyaka engu-3. I-Osteoporos Int 2002; 13: S160.
28. Greer, FR, Marshall, SP, Severson, RR, Smith, DA, Shearer, MJ, Pace, DG, noJoubert, PH Ukulungiselela okusha okuxubile kwemicellar kwe-vitamin K prophylaxis yomlomo: ukuqhathanisa okulawulwa ngokungahleliwe nokwenziwa kwemisipha kwezinsana ezincelisiwe . I-Arch .Dis Ingane 1998; 79: 300-305. Buka okungaqondakali.
29. UWentzien, T. H., O'Reilly, R. A., noKearns, P. J. Ukuhlola okulindelekile kokuguqulwa kwe-anticoagulant nge-vitamin K1 yomlomo ngenkathi kuqhubeka ukwelashwa kwe-warfarin kungashintshi. Isifuba 1998; 114: 1546-1550. Buka okungaqondakali.
30. UDuong, T. M., Plowman, B. K., Morreale, A. P., noJanetzky, K. Ukuhlaziya okubhekwayo nokubhekelekayo kokwelashwa kweziguli ezinamanzi amaningi. I-Pharmacotherapy 1998; 18: 1264-1270. Buka okungaqondakali.
31. Sato, Y., Honda, Y., Kuno, H., no-Oizumi, K. Menatetrenone bakhulisa i-osteopenia emilenzeni ethintekayo engasetshenziswanga yeziguli zikavithamini D- kanye no-K-abanesifo sohlangothi. Ithambo 1998; 23: 291-296. Buka okungaqondakali.
32. Ngenye indlela, M.A., Donovan, D., Harrison, L., McGinnis, J., noGinsberg, J. Umthamo ophansi wevithamini K yomlomo ophansi ngokuthembekile uguqula ngokweqile i-anticoagulation ngenxa ye-warfarin. Ukuhlanya. 1998; 79: 1116-1118. Buka okungaqondakali.
33. ULousberg, T. R., Witt, D. M., Beall, D. G., Carter, B. L., noMalone, D. C. Ukuhlolwa kwe-anticoagulation ngokweqile enhlanganweni yemodeli yokulondolozwa kwezempilo. I-Arch.Intern.Med. 3-9-1998; 158: 528-534. Buka okungaqondakali.
34. UFetrow, C.W, Overlock, T., noLeff, L. Ukuphikisana kwe-warfarin-induced hypoprothrombinemia ngokusebenzisa i-vitamin K1 engaphansi kwesilinganiso esincane. J.Clin.Pharmacol. 1997; 37: 751-757. Buka okungaqondakali.
35. Weibert, R.T, Le, D.T, Kayser, S. R., noRapaport, S. I. Ukulungiswa kwe-anticoagulation ngokweqile nge-vitamin K1 yomlomo ophansi. U-Ann.Intern.Med. 6-15-1997; 126: 959-962. Buka okungaqondakali.
36. Beker, L.T, Ahrens, R. A., Fink, R. J., O'Brien, M. E., Davidson, K. W., Sokoll, L. J., noSadowski, J. A. Umphumela we-vitamin K1 ukwengezwa kwesimo sevithamini K ezigulini ze-cystic fibrosis. UJ. Pediatr. Gastroenterol. Umsoco. 1997; 24: 512-517. Buka okungaqondakali.
37. Bakhshi, S., Deorari, A. K., Roy, S., Paul, V. K., noSingh, M. Ukuvinjelwa kokuntuleka kwe-vitamin K engaphansi kwesisekelo okuncike emazingeni e-PIVKA-II: indlela yomlomo uma kuqhathaniswa nemisipha. Indian Pediatr. 1996; 33: 1040-1043. Buka okungaqondakali.
38. UMakris, M., Greaves, M., Phillips, WS, Kitchen, S., Rosendaal, FR, no-Preston, EF Emergency oral anticoagulant reversal: ukusebenza ngokulinganayo kokungeniswa kwe-plasma efriziwe efriziwe kanye ne-clotting factor kugxila ekulungisweni kwe-coagulopathy . Ukuhlanya. 1997; 77: 477-480. Buka okungaqondakali.
39. Ulusahin, N., Arsan, S., no-Ertogan, F. Imiphumela ye-vitamin K prophylaxis yomlomo neyomzimba emithanjeni ye-PIVKA-II yokulinganisa ezinsaneni ezincelisayo eTurkey. I-Turk. J. Ingane. 1996; 38: 295-300. Buka okungaqondakali.
40. IGijsbers, B. L., Jie, K. S., noVermeer, C. Umphumela wokwakheka kokudla ekumungeni kukavithamini K kumavolontiya abantu. Br.J Nutr. 1996; 76: 223-229. Buka okungaqondakali.
41. UThijssen, H. H. noDkttij-Reijnders, isimo sikaM. J. Vitamin K kwizicubu zomuntu: ukuqongelela okuqondene nezicubu ze-phylloquinone ne-menaquinone-4. Br.J Nutr. 1996; 75: 121-127. Buka okungaqondakali.
42. UWhite, R. H., McKittrick, T., Takakuwa, J., Callahan, C., McDonell, M., noFihn, S. Ukuphathwa nokubikezela ukopha okusongela ukuphila ngesikhathi sokwelapha i-warfarin. I-National Consortium Yemitholampilo Ye-Anticoagulation. I-Arch.Intern.Med. 6-10-1996; 156: 1197-1201. Buka okungaqondakali.
43. USharma, R. K., Marwaha, N., Kumar, P., noNarang, A. Umphumela wevithamini K oncibilikiswa ngamanzi omlomo emazingeni e-PIVKA-II ezinganeni ezisanda kuzalwa. Indian Pediatr. 1995; 32: 863-867. Buka okungaqondakali.
44. Brousson, M. A. noKlein, M. C. Izingxabano ezizungeze ukuphathwa kukavithamini K ezinganeni ezisanda kuzalwa: ukubuyekeza. CMAJ. 2-1-1996; 154: 307-315. Buka okungaqondakali.
45. UCornelissen, E. A., Kollee, L. A., van Lith, T. G., Motohara, K., noMonnens, L. A. Ukuhlolwa komthamo wansuku zonke wama-micrograms angama-25 kavithamini K1 ukuvikela ukuntuleka kwamavithamini K ezinganeni ezincelisayo. UJ. Pediatr. Gastroenterol. Umsoco. 1993; 16: 301-305. Buka okungaqondakali.
46. Hogenbirk, K., Peters, M., Bouman, P., Sturk, A., noBuller, HA Umphumela wefomula uma uqhathanisa nokuncelisa ibele kanye ne-vitamin K1 eyengeziwe yokwengezwa kwamazinga okujikeleza kavithamini K1 kanye nezici zokunqanda i-vitamin K izinsana. Eur.J. Udokotela wezingane. 1993; 152: 72-74. Buka okungaqondakali.
47. UCornelissen, E. A., Kollee, L. A., De Abreu, R. A., Motohara, K., noMonnens, L. A. Ukuvimbela ukushoda kukavithamini K ebuntwaneni ngokuphathwa kwevithamini K. Acta Paediatr masonto onke. 1993; 82: 656-659. Buka okungaqondakali.
48. UKlebanoff, M. A., Read, J. S., Mills, J. L., noShiono, P. H. Ingozi yomdlavuza wezingane ngemuva kokuvezwa kwe-vitamin K. N.Engl.J.Med. 9-23-1993; 329: 905-908. Buka okungaqondakali.
49. UDickson, R. C., Stubbs, T. M., noLazarchick, J. Ukwelashwa kwe-vitamin K kokubeletha kosana olunesisindo esiphansi. NginguJ. J. Obstet. Gynecol. 1994; 170 (1 Pt 1): 85-89. Buka okungaqondakali.
50. UPengo, V., Banzato, A., Garelli, E., Zasso, A., noBiasiolo, A. Ukuguqulwa komphumela owedlulele we-anticoagulation ejwayelekile: umthamo ophansi womlomo we-phytonadione (uvithamini K1) uma kuqhathaniswa nokuyeka kwe-warfarin. Igazi Coagul. I-fibrinolysis 1993; 4: 739-741. Buka okungaqondakali.
51. Thorp, JA, Parriott, J., Ferrette-Smith, D., Meyer, BA, Cohen, GR, noJohnson, J. Antepartum uvithamini K kanye ne-phenobarbital yokuvimbela ukopha okungaphakathi emithanjeni enganeni esanda kuzalwa: okungahleliwe, okungaboni kabili, isilingo esilawulwa yi-placebo. Isikhubekiso. 1994; 83: 70-76. Buka okungaqondakali.
52. UMaurage, C., Dalloul, C., Moussa, F., Cara, B., Dudragne, D., Lion, N., no-Amedee-Manesme, O. [Ukusebenza kokuphathwa ngomlomo kwesisombululo se-micellaar se-vitamin K ngesikhathi isikhathi sokubeletha]. Arch.Pediatr. 1995; 2: 328-332. Buka okungaqondakali.
53. UTaberner, D. A., Thomson, J. M., noPoller, L. Ukuqhathaniswa kwe-prothrombin concentrate eyinkimbinkimbi kanye ne-vitamin K1 ekuguqulweni komlomo kwe-anticoagulant yomlomo. Br.Med.J. 7-10-1976; 2: 83-85. Buka okungaqondakali.
54. Glover, J. J. and Morrill, G. B. Ukwelashwa okulondolozayo kweziguli ezingaphezulu kwamandla. Isifuba 1995; 108: 987-990. Buka okungaqondakali.
55. UJie, K. S., Bots, M. L., Vermeer, C., Witteman, J. C., noGrobbee, D. E. Vitamin K amazinga okudla kanye ne-osteocalcin kwabesifazane abane-atherosclerosis engenayo ne-aortic: isifundo esisekelwe kubantu. I-Atherosclerosis 1995; 116: 117-123. Buka okungaqondakali.
56. USutherland, J. M., Glueck, H. I., noGleser, G. Isifo esibuhlungu somzimba esisanda kuzalwa. Ukuncelisa ibele njengento edingekayo ku-pathogenesis. Nginguye. J. Dis. Ingane 1967; 113: 524-533. Buka okungaqondakali.
57. UMotohara, K., Endo, F., noMatsuda, I. Ukushoda kukaVitamin K ezinganeni ezincelisa ibele ngenyanga eyodwa ubudala. UJ. Pediatr. Gastroenterol. Umsoco. 1986; 5: 931-933. Buka okungaqondakali.
58. UPomerance, J. J., Teal, J. G., Gogolok, J. F., Brown, S., noStewart, M. E. Maternally ophethwe ngokubeletha uvithamini K1: umphumela ekusebenzeni kwe-prothrombin ye-neonatal, isikhathi se-thromboplastin esinqunyiwe, kanye ne-intraventricular hemorrhage. Isikhubekiso. 1987; 70: 235-241. Buka okungaqondakali.
59. U-O'Connor, M. E. no-Addiego, J. E., Jr. Ukusetshenziswa kwe-vitamin K1 yomlomo ukuvimbela isifo sokopha sengane esanda kuzalwa. UJ. Pediatr. Ngo-1986; 108: 616-619. Buka okungaqondakali.
60. UMorales, W. J., Angel, J. L., O'Brien, W. F., Knuppel, R. A., noMarsalisi, F. Ukusetshenziswa kwe-vitamin K ngaphambi kokubeletha ekuvikeleni ukuphuma kwegazi kwasekuqaleni kwezinsana. NginguJ. J. Obstet. Gynecol. 1988; 159: 774-779. Buka okungaqondakali.
61. UMotohara, K., Endo, F., noMatsuda, I. Umphumela wokuphathwa kukavithamini K emazingeni e-acarboxy prothrombin (PIVKA-II) ezinganeni ezisanda kuzalwa. ILancet 8-3-1985; 2: 242-244. Buka okungaqondakali.
62. I-Propranolol ivimbela ukopha kokuqala kwamathumbu ezigulini ezingezona eze-cicrhotic. Umbiko wokugcina wesivivinyo esinamakhemikhali amaningi. Iphrojekthi ye-Italian Multicenter yePropranolol Ekuvimbeleni Ukopha. UJ. Hepatol. 1989; 9: 75-83. Buka okungaqondakali.
63. UKazzi, N. J., Ilagan, N. B., Liang, K. C., Kazzi, G. M., Poland, R. L., Grietsell, L. A., Fujii, Y., kanye namaBrans, Y. W. Ukuphathwa komama kwevithamini K akuyithuthukisi iphrofayili yokuqina yezinsana ezizalwe ngaphambi kwesikhathi. Izifo zezingane 1989; 84: 1045-1050. Buka okungaqondakali.
64. UYang, Y. M., Simon, N., Maertens, P., Brigham, S., noLiu, P. Ukuthuthwa komama-fetal kwe-vitamin K1 nemiphumela yako ekuhlanganiseni ezinganeni ezingaphambi kwesikhathi. UJ. Pediatr. 1989; 115: 1009-1013. Buka okungaqondakali.
65. UMartin-Lopez, JE, uCarlos-Gil, AM, uRodriguez-Lopez, R., uVillegas-Portero, R., uLuque-Romero, uL, noFlores-Moreno, S. [Iprophylactic vitamin K yokushoda kukavithamini K ukuphuma kwegazi osanda kuzalwa.]. Ipulazi.Ivangeli. 2011; 35: 148-55. Buka okungaqondakali.
66. Chow, C. K. Ukudla ukudla kwama-menaquinones kanye nengozi yokuhlaselwa umdlavuza nokufa. NginguJ. J.Clin. Nutr. 2010; 92: 1533-1534. Buka okungaqondakali.
67. Rees, K., Guraewal, S., Wong, YL, Majanbu, DL, Mavrodaris, A., Stranges, S., Kandala, NB, Clarke, A., noFranco, OH Ingabe ukusetshenziswa kwe-vitamin K kuhlotshaniswa ne-cardio-metabolic iziyaluyalu? Ukubuyekezwa okuhlelekile. IMatritas 2010; 67: 121-128. Buka okungaqondakali.
68. UNapolitano, M., Mariani, G., noLapecorella, M. Hereditary kuhlangene nokuntuleka kwezinto ezijiyile ezincike ku-vitamin K. Izintandane. J. Ezingavamile. 2010; 5:21. Buka okungaqondakali.
69. UDougherty, K. A., Schall, J. I., noStallings, V. A. Isimo sevithamini K esingaphansi naphezu kokungezelelwa ezinganeni nakubantu abadala abancane abane-cystic fibrosis. NginguJ. J.Clin. Nutr. 2010; 92: 660-667. Buka okungaqondakali.
70. UNovotny, J. A., Kurilich, A. C., Britz, S. J., Baer, ​​D. J., noClevidence, B. A.Ukufakwa kwe-Vitamin K kanye ne-kinetics ezifundweni zabantu ngemuva kokusebenzisa i-phylloquinone enelebula engu-13C kusuka ku-kale. Br.J Nutr. 2010; 104: 858-862. Buka okungaqondakali.
71. UJorgensen, F. S., Felding, P., Vinther, S., no-Andersen, G. E. Vitamin K kuma-neonates. Ukuphathwa kwe-Peroral kuqhathaniswa nemisipha. I-Acta Paediatr.Skand. 1991; 80: 304-307. Buka okungaqondakali.
72. UNimptsch, K., Rohrmann, S., Kaaks, R., noLinseisen, J.Ukudla kukavithamini K okudla maqondana nesifo somdlavuza nokufa: imiphumela evela eqenjini laseHeidelberg le-European Prospential Investigation kuCancer and Nutrition (EPIC-Heidelberg ). NginguJ. J.Clin. Nutr. 2010; 91: 1348-1358. Buka okungaqondakali.
73. I-Yamauchi, M., Yamaguchi, T., Nawata, K., Takaoka, S., no-Sugimoto, T. Ubudlelwano phakathi kwe-undercarboxylated osteocalcin kanye nokufakwa kukavithamini K, ukungena kwamathambo, kanye nokuqina kwamaminerali kwabesifazane abanempilo. Umtholampilo. 2010; 29: 761-765. Buka okungaqondakali.
74. I-Shea, i-MK, i-Booth, i-SL, i-Gundberg, i-CM, i-Peterson, i-JW, i-Waddell, i-C, i-Dawson-Hughes, i-B, ne-Saltzman, i-E.Ukukhuluphala kwabantu abadala kuhlotshaniswa kahle nokugxila kwezicubu ze-adipose ka-vitamin K futhi kuhlotshaniswa nokujikeleza izinkomba zesimo sikavithamini K kwabesilisa nabesifazane. UJ. Nutr. 2010; 140: 1029-1034. Buka okungaqondakali.
75. Ngokunye, uC. A., Crosby, D. D., noHenderson-Smart, D. J. Vitamin K ngaphambi kokubeletha ngaphambi kokuzalwa ngaphambi kokuvimbela ukopha okungapheli kokubeletha. Idatha yedatha yeCochrane. 2010; CD000229. Buka okungaqondakali.
76. Iwamoto, J. [Ukuphumelela kokulwa nokwaphuka kukavithamini K]. Umtholampilo ICalcium 2009; 19: 1805-1814. Buka okungaqondakali.
77. UStevenson, M., Lloyd-Jones, M., noPapaioannou, D. Vitamin K ukuvimbela ukuqhekeka kwabesifazane asebekhulile: ukubuyekezwa okuhlelekile nokuhlolwa kwezomnotho. I-Health Technol. Ukuhlolwa. 2009; 13: iii-134. Buka okungaqondakali.
78. UYoshiji, H., Noguchi, R., Toyohara, M., Ikenaka, Y., Kitade, M., Kaji, K., Yamazaki, M., Yamao, J., Mitoro, A., Sawai, M., Yoshida, M., Fujimoto, M., Tsujimoto, T., Kawaratani, H., Uemura, M., noFukui, H. Inhlanganisela ye-vitamin K2 kanye ne-angiotensin-eguqula i-enzyme inhibitor ikhuthaza ukuphindeka okwenyuka kwe-hepatocellular carcinoma. UJ. Hepatol. U-2009; 51: 315-321. Buka okungaqondakali.
79. U-Iwamoto, J., Matsumoto, H., noTakeda, T. Ukusebenza kwe-menatetrenone (i-vitamin K2) ekuqhekekeni kokunganqamuki kwe-vertebral ne-hip kwiziguli ezinezifo zemizwa: ukuhlaziywa kwe-meta kwezilingo ezintathu ezingahleliwe, ezilawulwayo. Umphenyi Wezidakamizwa. U-2009; 29: 471-479. Buka okungaqondakali.
80. UCrosier, MD, Peter, I., Booth, SL, Bennett, G., Dawson-Hughes, B., no-Ordovas, JM Association wokuhlukahluka kokulandelana kwamavithamini K epoxide reductase kanye nezakhi zofuzo ze-gamma-glutamyl carboxylase ngezinyathelo ze-vitamin K isimo. UJ. Nutr. Sci. Vitaminol. (Tokyo) 2009; 55: 112-119. Buka okungaqondakali.
81. U-Iwamoto, J., Sato, Y., Takeda, T., noMatsumoto, H. Ukwengeza nge-vitamin K ephezulu kunciphisa izehlakalo zokuqhekeka kwabesifazane be-postmenopausal: ukubuyekezwa kwezincwadi. Ukudla okunomsoco. U-2009; 29: 221-228. Buka okungaqondakali.
82. UShea, MK, O'Donnell, CJ, Hoffmann, U., Dallal, GE, Dawson-Hughes, B., Ordovas, JM, Price, PA, Williamson, MK, noBooth, SL Vitamin K ukwengeza kanye nokuqhubekeka komthambo we-coronary artery calcium kwabesilisa nabesifazane asebekhulile. NginguJ. J.Clin. Nutr. 2009; 89: 1799-1807. Buka okungaqondakali.
83. Izifinyezo zeziguli. Ingabe i-vitamin K iyasiza kubantu abathathe i-warfarin eningi kakhulu? U-Ann.Intern.Med. 3-3-2009; 150: I25. Buka okungaqondakali.
84. Kim, HS, Park, JW, Jang, JS, Kim, HJ, Shin, WG, Kim, KH, Lee, JH, Kim, HY, and Jang, MK Amanani okubikezela we-alpha-fetoprotein namaprotheni abangelwa ukungabikho kukavithamini K noma Umphikisi-II ku-hepat B B ehlobene negciwane le-hepatocellular carcinoma: isifundo esizayo. JClin, Gastroenterol. U-2009; 43: 482-488. Buka okungaqondakali.
85. Inoue, T., Fujita, T., Kishimoto, H., Makino, T., Nakamura, T., Nakamura, T., Sato, T., no Yamazaki, K. Ucwaningo olulawulwa ngokungahleliwe mayelana nokuvinjelwa kwe-osteoporotic fractures ( YOKUFUNDA): isifundo somtholampilo sesigaba IV samaphilisi we-15-mg menatetrenone. UJ. Bone Miner. IMetab 2009; 27: 66-75. Buka okungaqondakali.
86. Cheung, AM, Tile, L., Lee, Y., Tomlinson, G., Hawker, G., Scher, J., Hu, H., Vieth, R., Thompson, L., Jamal, S., no UJosse, R. Vitamin K ukwengeza kwabesifazane be-postmenopausal abane-osteopenia (isilingo se-ECKO): isilingo esilawulwa ngokungahleliwe. PLoS.Med. I-10-14-2008; 5: e196. Buka okungaqondakali.
87. Ishida, Y. [Vitamin K2]. Umtholampilo. I-Calcium 2008; 18: 1476-1482. Buka okungaqondakali.
88. Hathaway, WE, Isarangkura, PB, Mahasandana, C., Jacobson, L., Pintadit, P., Pung-Amritt, P., noGreen, GM Ukuqhathaniswa kwe-vitamin K prophylaxis yomlomo neye-parenteral yokuvimbela isifo se-hemorrhagic sekwephuzile osanda kuzalwa. UJ. Pediatr. 1991; 119: 461-464. Buka okungaqondakali.
89. Iwamoto, J., Takeda, T., noSato, Y. Indima kavithamini K2 ekwelapheni i-postmenopausal osteoporosis. I-Curr.Izidakamizwa Saf 2006; 1: 87-97. Buka okungaqondakali.
90. UMarti-Carvajal, A. J., Cortes-Jofre, M., noMarti-Pena, A. J. Vitamin K wokopha okuphezulu kwamathumbu ezigulini ezinezifo zesibindi. Idatha yedatha yeCochrane. 2008; CD004792. Buka okungaqondakali.
91. UDrury, D., Grey, V. L., Ferland, G., Gundberg, C., kanye namazwe, L. C. Ukusebenza komthamo ophezulu we-phylloquinone ekulungiseni ukuntuleka kukavithamini K ku-cystic fibrosis. J.Cyst.Fibros - izinhlelo zokusebenza ku-Google play 2008; 7: 457-459. Buka okungaqondakali.
92. IMacdonald, HM, McGuigan, FE, Lanham-New, SA, Fraser, WD, Ralston, SH, neReid, ukungena kweVitamin K1 kuhlotshaniswa nobuningi bamathambo futhi kunciphise ukubuyiswa kwamathambo kwabesifazane baseScotland bokuqala be-postmenopausal: abukho ubufakazi besakhi sofuzo Ukusebenzisana okungenamsoco ne-apolipoprotein E polymorphisms. NginguJ. J.Clin. Nutr. 2008; 87: 1513-1520. Buka okungaqondakali.
93. UNimptsch, K., Rohrmann, S., noLinseisen, J. Ukudla i-vitamin K kanye nengozi yomdlavuza wesibeletho eqenjini laseHeidelberg le-European Prospential Investigation into Cancer and Nutrition (EPIC-Heidelberg). NginguJ. J.Clin. Nutr. 2008; 87: 985-992. Buka okungaqondakali.
94. Hotta, N., Ayada, M., Sato, K., Ishikawa, T., Okumura, A., Matsumoto, E., Ohashi, T., noKakumu, S. Umphumela wevithamini K2 ukuphindeka kweziguli ezine i-hepatocellular carcinoma. IHepatogastroenterology 2007; 54: 2073-2077. Buka okungaqondakali.
95. U-Urquhart, D. S., Fitzpatrick, M., Cope, J., noJaffe, A. Vitamin K enquma amaphethini nokuqashwa kwempilo yamathambo ezinganeni zase-UK ezine-cystic fibrosis. J.Hum.Umsoco.Ukudla. 2007; 20: 605-610. Buka okungaqondakali.
96. Hosoi, T. [Ukwelashwa kwe-osteoporosis eyinhloko nge-vitamin K2]. Umtholampilo I-Calcium 2007; 17: 1727-1730. Buka okungaqondakali.
97. UJones, K. S., Bluck, L. J., Wang, L. Y., noCoward, W. A. ​​Indlela eqinile ye-isotope yokulinganisa ngasikhathi sinye i-vitamin K1 (phylloquinone) kinetics nokumunca. Eur.J.Clin.Umsoco. 2008; 62: 1273-1281. Buka okungaqondakali.
98. Knapen, M.H, Schurgers, L. J., noVermeer, C. Ukwengeza i-Vitamin K2 kuthuthukisa i-hip bone geometry nezikhombisi zamandla amathambo kwabesifazane be-postmenopausal. I-Osteoporos.Int. 2007; 18: 963-972. Buka okungaqondakali.
99. Maas, A.H, van der Schouw, Y. T., Beijerinck, D., Deurenberg, J. J., Mali, W. P., Grobbee, D. E., no-van der Graaf, Y.Ukudla kukaVitamin K nokubala emithanjeni yamabele. Maturitas 3-20-2007; 56: 273-279. Buka okungaqondakali.
100. UDentali, F., Ageno, W., noCrowther, M. Ukwelashwa kwe-coagulopathy ehambisana ne-coumarin: ukubuyekezwa okuhlelekile kanye nama-algorithms wokwelashwa ahlongozwayo. UJ. Thombomb. 2006; 4: 1853-1863. Buka okungaqondakali.
101. U-Liu, J., Wang, Q., Zhao, J. H., Chen, YH, noQin, G. L. I-corticosteroids ehlanganisiwe yokubeletha kanye nokwelashwa kwe-vitamin K yokuvimbela ukopha okwenzeka ngaphakathi kwezinsana ezingakazalwa ngaphambi kwesikhathi kwezinsana ezingaphansi kwamasonto angama-35 ukukhulelwa. J.Trop.Ingane Yezingane. 2006; 52: 355-359. Buka okungaqondakali.
102. U-Liu, J., Wang, Q., Gao, F., He, JW, noZhao, JH Ukuphathwa kokubeletha kwabakhulelwe kwe-vitamin K1 kuholela ekwandiseni imisebenzi yezici ze-coagulation ezixhomeke ku-vitamin K egazini lenkaba nasekunciphiseni izinga lezehlakalo wokwehla kwegazi okwenziwa nge-periventricular-intraventricular ezinganeni ezingakazalwa ngaphambi kwesikhathi. UJerlinat. 2006; 34: 173-176. Buka okungaqondakali.
103. UDezee, K. J., Shimeall, W. T., Douglas, K. M., Shumway, N. M., no-O’malley, P. G. Ukwelashwa kwe-anticoagulation ngokweqile nge-phytonadione (vitamin K): ukuhlaziywa kwe-meta. I-Arch.Intern.Med. 2-27-2006; 166: 391-397. Buka okungaqondakali.
104. Thijssen, H. H., Vervoort, L. M., Schurgers, L. J., noShearer, M. J. Menadione iyi-metabolite kavithamini womlomo K. Br.J Nutr. 2006; 95: 260-266. Buka okungaqondakali.
105. UGoldstein, JN, Thomas, SH, Frontiero, V., Joseph, A., Engel, C., Snider, R., Smith, EE, Greenberg, SM, noRosand, J. Isikhathi sokuphathwa okusha kwe-plasma efriziwe nokulungiswa okusheshayo ye-coagulopathy ekuqothulweni kwegazi okuhlobene ne-warfarin.Unhlangothi 2006; 37: 151-155. Buka okungaqondakali.
106. Shetty, H. G., Backhouse, G., Bentley, D. P., noRoutledge, P. A. Ukuguqulwa okusebenzayo kwe-warfarin-indened anticoagulation ngokweqile nge-vitamin K1 ephansi. Ukuhlanya. 1-23-1992; 67: 13-15. Buka okungaqondakali.
107. U-Ageno, W., Garcia, D., Silingardi, M., Galli, M., noCrowther, M. Isivivinyo esingahleliwe ngokuqhathanisa i-1 mg ye-vitamin K yomlomo ngaphandle kokwelapha ekuphathweni kwe-coagulopathy ehlobene ne-warfarin ezigulini ezinomshini ama-valve enhliziyo. UJ. Amahora. Cardiol. 8-16-2005; 46: 732-733. Buka okungaqondakali.
108. IVillines, T. C., Hatzigeorgiou, C., Feuerstein, I. M., O'malley, P. G., noTaylor, A. J. Vitamin K1 ukudla kanye nokubalwa kwe-coronary. Umthambo Dis. 2005; 16: 199-203. Buka okungaqondakali.
109. I-Yasaka, M., Sakata, T., Naritomi, H., neMinematsu, K. Umthamo omuhle we-prothrombin concentrate yokuguqula okunamandla kwe-anticoagulation yomlomo. I-Thromb.Izimali. 2005; 115: 455-459. Buka okungaqondakali.
110. Sato, Y., Honda, Y., Hayashida, N., Iwamoto, J., Kanoko, T., noSatoh, K. Ukushoda kukaVitamin K kanye ne-osteopenia kwabesifazane asebekhulile abanesifo i-Alzheimer's. I-Arch.Phys.Med.Rehabil. 2005; 86: 576-581. Buka okungaqondakali.
111. Sato, Y., Kanoko, T., Satoh, K., no-Iwamoto, J. Menatetrenone novithamini D2 abanezithasiselo ze-calcium zivimbela ukuqhekeka okungenamgogodla kwabesifazane asebekhulile abanesifo i-Alzheimer's. Ithambo 2005; 36: 61-68. Buka okungaqondakali.
112. Sasaki, N., Kusano, E., Takahashi, H., Ando, ​​Y., Yano, K., Tsuda, E., no-Asano, Y. I-Vitamin K2 ivimbela ukulahleka kwethambo okubangelwa i-glucocorticoid ngokwengxenye ngokuvimbela ukunciphisa i-osteoprotegerin (OPG). UJ Bone Miner, iMetab 2005; 23: 41-47. Buka okungaqondakali.
113. UKalkwarf, H. J., Khoury, J. C., Bean, J., no-Elliot, J. G. Vitamin K, ukubuyiswa kwamathambo, nobukhulu bamathambo emantombazaneni. NginguJ. J.Clin. Nutr. 2004; 80: 1075-1080. Buka okungaqondakali.
114. UHabu, D., Shiomi, S., Tamori, A., Takeda, T., Tanaka, T., Kubo, S., noNishiguchi, S. Indima ye-vitamin K2 ekwakheni i-hepatocellular carcinoma kwabesifazane abane-cirrhosis yegciwane kwesibindi. I-JAMA 7-21-2004; 292: 358-361. Buka okungaqondakali.
115. UDentali, F. no-Ageno, W. Ukuphathwa kwe-coagulopathy ehlobene ne-coumarin esigulini esingapheli igazi: ukubuyekeza okuhlelekile. IHaematologica 2004; 89: 857-862. Buka okungaqondakali.
116. ULubetsky, A., Hoffman, R., Zimlichman, R., Eldor, A., Zvi, J., Kostenko, V., noBrenner, B. Ukusebenza nokuphepha kwe-prothrombin complex concentrate (Octaplex) yokuguqula ngokushesha i-anticoagulation yomlomo. I-Thromb.Izimali. 2004; 113: 371-378. Buka okungaqondakali.
117. UBraam, L. A., Knapen, M.H, Geusens, P., Brouns, F., noVermeer, C. Izici ezithinta ukulahleka kwamathambo kubagijimi besifazane ababekezelayo: isifundo seminyaka emibili sokulandelela. Am. J. Ezemidlalo Med. 2003; 31: 889-895. Buka okungaqondakali.
118. Lubetsky, A., Yonath, H., Olchovsky, D., Loebstein, R., Halkin, H., no-Ezra, D. Ukuqhathaniswa kwe-oral vs intravenous phytonadione (vitamin K1) ezigulini ezine-anticoagulation ngokweqile: okungahle kulawulwe ngokungahleliwe funda. I-Arch.Intern.Med. 11-10-2003; 163: 2469-2473. Buka okungaqondakali.
119. UBraam, L. A., Knapen, M.H, Geusens, P., Brouns, F., Hamulyak, K., Gerichhausen, M. J., noVermeer, C. Ukwengeza i-Vitamin K1 kubuyisa ukulahleka kwamathambo kwabesifazane be-postmenopausal abaphakathi kweminyaka engama-50 nengu-60 ubudala. Izicubu Int. 2003; 73: 21-26. Buka okungaqondakali.
120. I-Cornelissen, i-EA, i-Kollee, i-LA, i-De Abreu, i-RA, i-van Baal, i-JM, i-Motohara, i-K., i-Verbruggen, i-B, ne-Monnens, i-LA Imiphumela ye-vitamin K prophylaxis yomlomo ne-intramuscular ku-vitamin K1, i-PIVKA-II, nokuvala izici ezinganeni ezinceliswe ibele. I-Arch. Dis. Ingane 1992; 67: 1250-1254. Buka okungaqondakali.
121. UMalik, S., Udani, R. H., Bichile, S. K., Agrawal, R. M., Bahrainwala, A.T, noTilaye, S. Ucwaningo lokuqhathanisa i-vitamin K yomlomo nejojowe. Indian Pediatr. 1992; 29: 857-859. Buka okungaqondakali.
122. I-VIETTI, T. J., MURPHY, T. P., JAMES, J. A., ne-PRITCHARD, J. A. Ukubhekelwa ekusetshenzisweni kwe-vithamini Kin kosana olusanda kuzalwa nge-prophylactic. UJ. Pediatr. 1960; 56: 343-346. Buka okungaqondakali.
123. I-Tabb, MM, Sun, A., Zhou, C., Grun, F., Errandi, J., Romero, K., Pham, H., Inoue, S., Mallick, S., Lin, M., Forman , BM, neBlumberg, B. Ukulawulwa kwe-Vitamin K2 kwe-bone homeostasis kulamulelwa yi-steroid ne-xenobiotic receptor SXR. UJ Biol. UChem. 11-7-2003; 278: 43919-43927. Buka okungaqondakali.
124. USorensen, B., Johansen, P., Nielsen, G. L., Sorensen, J. C., no-Ingerslev, J. Reversal of the International Normalized Ratio with recombinant activated factor VII in central nervous system shed during warfarin thromboprophylaxis: clinical and biochemical biochemical. Igazi Coagul. I-fibrinolysis 2003; 14: 469-477. Buka okungaqondakali.
125. UPoli, D., Antonucci, E., Lombardi, A., Gensini, GF, Abbate, R., noPrisco, D. Ukuphepha nokusebenza kolawulo olusezingeni eliphansi lomlomo wevithamini K1 ekuphathweni kweziguli ezingaphandle kwe-warfarin noma i-acenocoumarol ngokweqile i-anticoagulation. IHaematologica 2003; 88: 237-238. Buka okungaqondakali.
126. UYasaka, M., Sakata, T., Minematsu, K., noNaritomi, H. Ukulungiswa kwe-INR nge-prothrombin concentrate eyinkimbinkimbi kanye novithamini K ezigulini ezine-warfarin ezihlobene nenkinga yokopha. I-Thromb.Izimali. 10-1-2002; 108: 25-30. Buka okungaqondakali.
127. IBooth, SL, Broe, KE, Gagnon, DR, Tucker, KL, Hannan, MT, McLean, RR, Dawson-Hughes, B., Wilson, PW, Cupples, LA, noKiel, DP Vitamin K ukudla kanye nobuningi bamaminerali amathambo kwabesifazane nabesilisa. NginguJ. J.Clin. Nutr. 2003; 77: 512-516. Buka okungaqondakali.
128. UDeveras, R. A. noKessler, C. M. Ukubuyiselwa emuva kwe-warfarin-indased anticoagulation nge-recombinant factor factor VIIa concentrate. U-Ann.Intern.Med. 12-3-2002; 137: 884-888. Buka okungaqondakali.
129. URiegert-Johnson, D. L. noVolcheck, G. W. Isimo se-anaphylaxis kulandela i-phytonadione efakwa emithanjeni (i-vitamin K1): ukubuyekezwa kweminyaka engu-5 yokubuyela emuva. U-Ann Isifo Sokulwa Nezifo Somoya I-Immunol 2002; 89: 400-406. Buka okungaqondakali.
130. Ngokunye, MA, Douketis, JD, Schnurr, T., Steidl, L., Mera, V., Ultori, C., Venco, A., no-Ageno, W. I-vitamin K yomlomo yehlisa isilinganiso esijwayelekile somhlaba wonke ngokushesha okukhulu kunangaphansi kwesikhumba uvithamini K ekwelashweni kwe-coagulopathy ehlobene ne-warfarin. Isivivinyo esingahleliwe, esilawulwayo. U-Ann.Intern.Med. 8-20-2002; 137: 251-254. Buka okungaqondakali.
131. U-Ageno, W., Ngokunye, M., Steidl, L., Ultori, C., Mera, V., Dentali, F., Squizzato, A., Marchesi, C., noVenco, A. Umthamo ophansi we-vitamin K yomlomo. ukuguqula i-coagulopathy ebangelwa yi-acenocoumarol: isilingo esilawulwa ngokungahleliwe. Ukuhlanya. 2002; 88: 48-51. Buka okungaqondakali.
132. Sato, Y., Honda, Y., Kaji, M., Asoh, T., Hosokawa, K., Kondo, I., noSatoh, K. Ukuvuselelwa kwe-osteoporosis yi-menatetrenone ezigulini zesifazane esezikhulile zesifo sikaParkinson ezine-vitamin D . Ithambo 2002; 31: 114-118. Buka okungaqondakali.
133. U-Olson, R. E., Chao, J., Graham, D., Bates, M. W., no Lewis, J. H. Ingqikithi yomzimba i-phylloquinone kanye nokungena kwayo ezifundweni zabantu emazingeni amabili okudla kukavithamini K. Br.J Nutr. 2002; 87: 543-553. Buka okungaqondakali.
134. U-Andersen, P. no-Godal, H. C. Ukwehliswa okungaqageli komsebenzi we-anticoagulant we-warfarin ngamanani amancane ka-vitamin K. Acta Med. Izwe. Ngo-1975; 198: 269-270. Buka okungaqondakali.
135. U-Preston, F. E., Laidlaw, S. T., Sampson, B., noKhishi, S. Ukubuyiselwa emuva okusheshayo kwe-anticoagulation yomlomo nge-warfarin nge-prothrombin complex concentrate (Beriplex): ukusebenza nokuphepha ezigulini ezingama-42. UBr. J. Haematol. 2002; 116: 619-624. Buka okungaqondakali.
136. U-Evans, G., Luddington, R., noBaglin, T. Beriplex P / N babuyisela emuva ukuqina okukhulu kwe-warfarin ngokushesha nangokuphelele ezigulini ezethula ukopha okukhulu. UBr. J. Haematol. 2001; 115: 998-1001. Buka okungaqondakali.
137. Iwamoto, J., Takeda, T., no-Ichimura, S. Umphumela we-menatetrenone ekucineni kwamaminerali wamathambo kanye nokuqubuka kokuqhekeka kwe-vertebral kwabesifazane be-postmenopausal abane-osteoporosis: ukuqhathanisa nomphumela we-etidronate. J.Orthop.Sci. 2001; 6: 487-492. Buka okungaqondakali.
138. Sato, Y., Kaji, M., Tsuru, T., Satoh, K., noKondo, I. Ukushoda kukaVitamin K kanye ne-osteopenia kwabesifazane asebekhulile abangavithamini D abanesifo sikaParkinson. I-Arch.Phys.Med.Rehabil. 2002; 83: 86-91. Buka okungaqondakali.
139. UWatson, H.G., Baglin, T., Laidlaw, S. L., Makris, M., noPreston, F. E. Ukuqhathaniswa kokusebenza kanye nezinga lokuphendula ku-Vitamin K ngomlomo nangomjovo wokuguqula ukuguqulwa kwe-anticoagulation nge-warfarin. UBr. J. Haematol. 2001; 115: 145-149. Buka okungaqondakali.
140. UKumar, D., Greer, F. R., Super, D. M., Suttie, J. W., noMoore, J. J. Vitamin K isimo sezinsana ezingaphambi kwesikhathi: imiphumela yezincomo zamanje. Izifo zezingane 2001; 108: 1117-1122. Buka okungaqondakali.
141. UNishiguchi, S., Shimoi, S., Kurooka, H., Tamori, A., Habu, D., Takeda, T., noKubo, S. Isivivinyo somshayeli esingahleliwe sevithamini K2 sokulahleka kwethambo ezigulini ezine-cirrhosis eyinhloko . UJ. Hepatol. 2001; 35: 543-545. Buka okungaqondakali.
142. Wilson, DC, Rashid, M., Durie, PR, Tsang, A., Kalnins, D., Andrew, M., Corey, M., Shin, J., Tullis, E., noPencharz, PB Ukwelashwa kwamavithamini K ukuntuleka kwe-cystic fibrosis: Ukusebenza kwenhlanganisela yansuku zonke yama-vithamini ancibilika ngamafutha UJ. Pediatr. 2001; 138: 851-855. Buka okungaqondakali.
143. UPendry, K., Bhavnani, M., noShwe, K. Ukusetshenziswa kwe-vitamin K yomlomo ukuguqula ukwenziwa kwe-warfarinization ngokweqile. UBr. J. Haematol. 2001; 113: 839-840. Buka okungaqondakali.
144. UFondevila, C. G., Grosso, S. H., Santarelli, M.T, noPinto, M. D. Ukubuyiselwa emuva kwe-anticoagulation yomlomo ngokweqile ngomthamo ophansi womlomo kavithamini K1 uma kuqhathaniswa nokuyekiswa kwe-acenocoumarine. Ucwaningo olulindelekile, oluhleliwe, oluvulekile. Igazi Coagul. I-fibrinolysis 2001; 12: 9-16. Buka okungaqondakali.
145. ICartmill, M., Dolan, G., Byrne, J. L., kanye neByrne, P. O. Prothrombin ukugxila okuyinkimbinkimbi kokuguqulwa komlomo kwe-anticoagulant ezimeni eziphuthumayo ze-neurosurgical. UBr. J. Neurosurg. 2000; 14: 458-461. Buka okungaqondakali.
146. Iwamoto, J., Takeda, T., no-Ichimura, S. Umphumela wokuphathwa okuhlangene kwe-vitamin D3 no-vitamin K2 ekucineni kwamaminerali amathambo omgogodla we-lumbar kwabesifazane be-postmenopausal abane-osteoporosis. J.Orthop.Sci. 2000; 5: 546-551. Buka okungaqondakali.
147. Ngokuvamile, MA, Julian, J., McCarty, D., Douketis, J., Kovacs, M., Biagoni, L., Schnurr, T., McGinnis, J., Gent, M., Hirsh, J., no UGinsberg, J. Ukwelashwa kwe-coagulopathy ehlobene ne-warfarin ne-vitamin K yomlomo: isilingo esilawulwa ngokungahleliwe. ILancet 11-4-2000; 356: 1551-1553. Buka okungaqondakali.
148. UPuckett, R. M. no-Offringa, M. Prophylactic uvithamini K wokushoda kukavithamini K opha ama-neonates. Idatha yedatha yeCochrane. 2000; CD002776. Buka okungaqondakali.
149. Patel, R. J., Witt, D. M., Saseen, J. J., Tillman, D. J., noWilkinson, D. S. Randomised, placebo-controlled trial of oral phytonadione for anticoagulation ngokweqile. I-Pharmacotherapy 2000; 20: 1159-1166. Buka okungaqondakali.
150. UHung, A., Singh, S., noTait, R. C. Ucwaningo oluzobekwa ngokungahleliwe ukuthola isilinganiso esifanele sevithamini K efakwa emthanjeni ekubuyiseleni emuva i-warfarinization eyeqile. UBr. J. Haematol. 2000; 109: 537-539. Buka okungaqondakali.
151. UHylek, E. M., Chang, Y. C., Skates, S. J., Hughes, R. A., no-Singer, D. E. Ucwaningo olulindelekile lwemiphumela yeziguli ezihamba ngamagciwane ezine-anticoagulation ngokweqile ye-warfarin. I-Arch.Intern.Med. 6-12-2000; 160: 1612-1617. Buka okungaqondakali.
152. Brophy, M.T, Fiore, L. D., noDeykin, D. Ukwelashwa Okuphansi Kwe-Dose Vitamin K Ezigulini Ezinama-Anticoagulated ngokweqile: Isifundo Sokuthola Idosi. I-Thrombolysis. 1997; 4: 289-292. Buka okungaqondakali.
153. URaj, G., Kumar, R., noMcKinney, W. P. Isikhathi sesikhathi sokuguqulwa komphumela we-anticoagulant we-warfarin nge-phytonadione efakwa ngaphakathi nangaphansi. I-Arch.Intern.Med. 12-13-1999; 159: 2721-2724. Buka okungaqondakali.
154. Byrd, D. C., Stephens, M. A., Hamann, G. L., noDorko, C. I-phytonadione engaphansi kokuguqulwa kokuphakanyiswa okubangelwa yi-warfarin kwe-International Normalized Ratio. Ngingu. J. Health Syst. Umkhiqizo. 11-15-1999; 56: 2312-2315. Buka okungaqondakali.
155. UBoulis, N. M., Bobek, M. P., Schmaier, A., noHoff, J. T. Ukusetshenziswa kwe-factor IX complex in hemorrhage ehlobene ne-warfarin. I-Neurosurgery 1999; 45: 1113-1118. Buka okungaqondakali.
156. URashid, M., Durie, P., Andrew, M., Kalnins, D., Shin, J., Corey, M., Tullis, E., noPencharz, P. B. Ukusabalala kokushoda kukavithamini K ku-cystic fibrosis. NginguJ. J.Clin. Nutr. 1999; 70: 378-382. Buka okungaqondakali.
157. UBooth, S. L., O'Brien-Morse, M. E., Dallal, G. E., Davidson, K. W., noGundberg, C. M. Impendulo yesimo sevithamini K ekuthathweni okuhlukahlukene nemithombo yokudla okunothe kwe-phylloquinone: ukuqhathaniswa kwabantu abadala nabadala. NginguJ. J.Clin. Nutr. 1999; 70: 368-377. Buka okungaqondakali.
158. I-Somekawa, Y., Chigughi, M., Harada, M., ne-Ishibashi, T. Ukusetshenziswa kwe-vitamin K2 (menatetrenone) kanye ne-1,25-dihydroxyvitamin D3 ekuvimbeleni ukulahleka kwethambo okubangelwa yi-leuprolide. UJ. Clin. Endocrinol. IMetab 1999; 84: 2700-2704. Buka okungaqondakali.
159. Sato, Y., Tsuru, T., Oizumi, K., noKaji, M. Vitamin K ukuntuleka kanye ne-osteopenia emilenzeni ethintekile engasetshenziswanga yeziguli ezinesifo sikavithamini osekhulile. Am.J.Phys.Med.Rehabil. 1999; 78: 317-322. Buka okungaqondakali.
160. UNee, R., Doppenschmidt, D., uDonovan, uD. J., no-Andrews, uT. C. Intravenous versus subcutaneous vitamin K1 ekubuyiseleni emuva i-anticoagulation yomlomo eyeqile. NginguJ. Cardiol. 1-15-1999; 83: 286-287. Buka okungaqondakali.
161. UPenning-van Beest, F. J., Rosendaal, F. R., Grobbee, D. E., van, Meegen E., noStricker, B. H. Course of the International Normalized Ratio ekuphenduleni i-vitamin K1 yomlomo ezigulini ezingaphezulu kwe-phenprocoumon. UBr. J. Haematol. 1999; 104: 241-245. Buka okungaqondakali.
162. UBolton-Smith, C., McMurdo, ME, Paterson, CR, Mole, PA, Harvey, JM, Fenton, ST, Prynne, CJ, Mishra, GD, noShearer, MJ Isivivinyo seminyaka emibili esilawulwa ngokungahleliwe se-vitamin K1 (phylloquinone ) novithamini D3 kanye ne-calcium empilweni yamathambo yabesifazane asebekhulile. J. Bone Umvukuzi. 2007; 22: 509-519. Buka okungaqondakali.
163. U-Ishida, Y. noKawai, S. Ukusebenza ngokuqhathaniswa kwe-hormone replacement therapy, i-etidronate, i-calcitonin, i-alfacalcidol, ne-vitamin K kwabesifazane be-postmenopausal abane-osteoporosis: Isifundo Sokuvimbela I-Yamaguchi Osteoporosis. Ngingu. J. Med. 10-15-2004; 117: 549-555. Buka okungaqondakali.
164. UBooth SL, uGolly I, uSacheck JM, et al. Umphumela we-vitamin E supplementation kwisimo se-vitamin K kubantu abadala abanesimo esijwayelekile se-coagulation. Ngingu-J J Nutriti Womtholampilo. 2004; 80: 143-8. Buka okungaqondakali.
165. I-Wostmann BS, iKnight PL. Ukuphikisana phakathi kwamavithamini A no-K kusilinganiso segciwane. J Umsoco. Ngo-1965; 87: 155-60. Buka okungaqondakali.
166. UKim JS, uNafziger AN, uGaedigk A, et al. Imiphumela ye-vitamin K yomlomo ku-S- no-R-warfarin pharmacokinetics kanye ne-pharmacodynamics: ukuphepha okuthuthukisiwe kwe-warfarin njengophenyo lwe-CYP2C9. UJ Clin Pharmacol. 2001 Julayi; 41: 715-22. Buka okungaqondakali.
167. Ukuqondiswa kukavithamini K wokudla: isu elisebenzayo lokulawula okuzinzile kwe-anticoagulation yomlomo? Umsoco Rev. 2010; 68: 178-81. Buka okungaqondakali.
168. Ngokunye MA, Ageno W, Garcia D, et al. I-vitamin K yomlomo iqhathaniswa ne-placebo ukulungisa i-anticoagulation eyeqile ezigulini ezithola i-warfarin: isilingo esingahleliwe. U-Ann Intern Med. U-2009; 150: 293-300. Buka okungaqondakali.
169. UJagannath VA, Fedorowicz Z, Thaker V, Chang AB. Ukwengeza i-Vitamin K ye-cystic fibrosis. ICochrane Database Syst Rev. 2011;: CD008482. Buka okungaqondakali.
170. I-Miesner AR, iSullivan TS. Isilinganiso esiphakeme samazwe omhlaba esivela ku-vitamin K sengezelela ukuyekiswa. I-Ann Pharmacother 2011; 45: e2. Buka okungaqondakali.
171. U-Ansell J, uHirsh J, uHylek E, et al. I-Pharmacology kanye nokuphathwa kwabaphikisi bakavithamini K: I-American College of Chest Physicians Guid-based Clinical Practice Guidelines (8th Edition). Isifuba 2008; 133: 160S-98S. Buka okungaqondakali.
172. Ukuqhuma kwe-EK, iRosendaal FR. UVan Der Meer FJ. Ukwengezwa kwe-vitamin K yansuku zonke kuthuthukisa ukuqina kwe-anticoagulant. UJ Thromb Haemost 2007; 5: 2043-8. Buka okungaqondakali.
173. UReese AM, uFarnett LE, uLyons RM, et al. I-vitamin K enomthamo ophansi yokwengeza ukulawula i-anticoagulation. I-Pharmacotherapy 2005; 25: 1746-51. Buka okungaqondakali.
174. I-Sconce E, Avery P, Wynne H, Kamali F.Ukuxhaswa kwe-Vitamin K kungathuthukisa ukuzinza kwe-anticoagulation yeziguli ezinokuhluka okungaqondakali ekuphenduleni i-warfarin. Igazi 2007; 109: 2419-23. Buka okungaqondakali.
175. UKurnik D, uLobestein R, uRabinovitz H, et al. Izithako zokwengeza i-vitamin K1 eziqukethe i-counter-the-counter ziphazamisa i-warfarin anticoagulation ezigulini ezigcwele uvithamini K1. UTromb Haemost 2004; 92: 1018-24. Buka okungaqondakali.
176. USconce E, uKhan T, uMason J, et al. Iziguli ezinokulawulwa okungazinzile zinokudla okungampofu kokudla i-vitamin K uma kuqhathaniswa neziguli ezinokulawulwa okuzinzile kwe-anticoagulation. UTromb Haemost 2005; 93: 872-5. Buka okungaqondakali.
177. UTamura T, Morgan SL, Takimoto H. Vitamin K kanye nokuvinjelwa kokuhlukana (incwadi nezimpendulo). I-Arch Int Med 2007; 167: 94-5. Buka okungaqondakali.
178. UBeulens JW, uBots ML, u-Atsma F, et al. Ukudla okuphezulu kwe-menaquinone kuhlotshaniswa nokunciphisa ukubalwa kwe-coronary. I-Atherosclerosis 2009; 203: 489-93. Buka okungaqondakali.
179. UBooth SL, uDallal G, uShea MK, et al. Umphumela we-vitamin K supplementation ekulahlekelweni kwethambo kwabesilisa nabesifazane asebekhulile. UJ Clin Endocrinol Metab 2008; 93: 1217-23. Buka okungaqondakali.
180. Ama-Schurgers LJ, Dissel PE, Spronk HM, et al. Indima kavithamini K namaprotheni ancike ku-vitamin K ekubalweni kwamathambo. Z Kardiol 2001; 90 (suppl 3): 57-63. Buka okungaqondakali.
181. UGeleijnse JM, uVermeer C, uGrobbee DE, et al. Ukudla kwe-menaquinone kuhlotshaniswa nengozi encishisiwe yesifo senhliziyo: Isifundo seRotterdam. UJ Nutriti 2004; 134: 3100-5. Buka okungaqondakali.
182. I-Al-Terkait F, uCharalambous H. Seagulopathy engaphelele kuya ku-vitamin K ekuguleni okunesifo samathumbu amancane nomdlavuza we-rectal. ILancet Oncol 2006; 7: 188. Buka okungaqondakali.
183. UYoshikawa H, Yamazaki S, Watanabe T, Abe T. Vitamin K ukuntula ezinganeni ezikhubazeke kakhulu. J Ingane Neurol 2003; 18: 93-7. Buka okungaqondakali.
184. ISchoon EJ, uMuller MC, uVermeer C, et al. Isimo se-serum ephansi nethambo lika-vitamin K ezigulini ezinesifo seCrohn eside: esinye isici se-pathogenetic se-osteoporosis kwisifo sikaCrohn? Isisu 2001; 48: 473-7. Buka okungaqondakali.
185. USzulc P, uMeunier PJ. Ingabe ukushoda kukavithamini K kuyingcuphe ye-osteoporosis kwisifo sikaCrohn? ILancet 2001; 357: 1995-6. Buka okungaqondakali.
186. UDuggan P, O'Brien M, uKiely M, et al. Isimo sikaVitamin K ezigulini ezinesifo sikaCrohn kanye nobudlelwano nokutholwa kwethambo. NginguJ J Gastroenterol 2004; 99: 2178-85. Buka okungaqondakali.
187. UCockayne S, u-Adamson J, uLanham-New S, et al. Vitamin K nokuvinjelwa kokuqhekeka. ukubuyekezwa okuhlelekile nokuhlaziywa kwe-meta-kwezivivinyo ezilawulwa ngokungahleliwe. I-Arch Intern Med 2006; 166: 1256-61. Buka okungaqondakali.
188. URejnmark L, uVestergaard P, uCharles P, et al. Awukho umthelela wokudla kukavithamini K kumathambo amaminerali nengozi yokuphuka kwabesifazane be-perimenopausal. I-Osteoporos Int 2006; 17: 1122-32. Buka okungaqondakali.
189. URobert D, uJorgetti V, uLeclercq M, et al. Ingabe i-vitamin K eyeqile yenza ukubalwa kwe-ectopic ezigulini ze-hemodialysis? Umtholampilo uNephrol 1985; 24: 300-4. Buka okungaqondakali.
190. UTam DA Jr, Myer EC. I-coagulopathy ethembele ku-Vitamin K enganeni ethola ukwelashwa kwe-anticonvulsant. J Ingane Neurol 1996; 11: 244-6. Buka okungaqondakali.
191. UKeith DA, uGundberg CM, uJapour A, et al. Amaprotheni ancike ku-Vitamin K nemithi elwa ne-anticonvulsant. I-Clin Pharmacol Ther 1983; 34: 529-32. Buka okungaqondakali.
192. UThorp JA, uGaston L, iCaspers DR, uPal ML. Imiqondo yamanje kanye nezimpikiswano ekusetshenzisweni kukavithamini K. Izidakamizwa 1995; 49: 376-87. Buka okungaqondakali.
193. IBleyer WA, iSkinner AL. Ukopha okubulalayo kwe-neonatal ngemuva kokwelashwa komama kwe-anticonvulsant. I-JAMA 1976; 235: 626-7.
194. URenzulli P, Tuchschmid P, Eich G, et al. Ukushoda kokuqala kukavithamini K ukuphuma kwegazi ngemuva kokudla kukamama kwe-phenobarbital: ukuphathwa kokopha okukhulu ngaphakathi ngokungenelela okuncane kokuhlinzwa. I-Eur J Pediatr 1998; 157: 663-5. Buka okungaqondakali.
195. UCornelissen M, uSteegers-Theunissen R, uKollee L, et al. Ukwengezwa kukavithamini K kwabesifazane abakhulelwe abathola ukwelashwa kwe-anticonvulsant kuvimbela ukuntuleka kwe-vitamin K ebelethayo. NginguJ J Obstet Gynecol 1993; 168: 884-8. Buka okungaqondakali.
196. UCornelissen M, uSteegers-Theunissen R, uKollee L, et al. Ukwanda kwesimo sokuntuleka kwe-vitamin K esanda kuzalwa okubangelwa ukwelashwa kwe-anticonvulsant yomama. NginguJ J Obstet Gynecol 1993; 168: 923-8. Buka okungaqondakali.
197. IMacWalter RS, iFraser HW, i-Armstrong KM. I-Orlistat ithuthukisa umphumela we-warfarin. U-Ann Pharmacother 2003; 37: 510-2. Buka okungaqondakali.
198. UVroonhof K, van Rijn HJ, van Hattum J. Vitamin K ukushoda nokuphuma kwegazi ngemuva kokusebenzisa isikhathi eside i-cholestyramine. UNeth J Med 2003; 61: 19-21. Buka okungaqondakali.
199. UVan Steenbergen W, Vermylen J. Reversible hypoprothrombinemia esigulini esine-cirrhosis eyinhloko ye-biliary ephethwe nge-rifampicin. NginguJ J Gastroenterol 1995; 90: 1526-8. Buka okungaqondakali.
200. UKobayashi K, uHaruta T, uMaeda H, et al. Ukopha ebuchosheni okuhambisana nokushoda kukavithamini K kwisifo sofuba esibelethwe eselashwa nge-isoniazid ne-rifampin. I-Pediatr Infect Dis J 2002; 21: 1088-90. Buka okungaqondakali.
201. Sattler FR, Weitekamp MR, Ballard JO. Kungenzeka ukopha ngama-antibiotic amasha we-beta-lactam. U-Ann Intern Med 1986; 105: 924-31. Buka okungaqondakali.
202. I-Bhat RV, Deshmukh CT. Ucwaningo ngesimo sikaVitamin K ezinganeni ekwelashweni isikhathi eside kwama-antibiotic. I-Indian Pediatr 2003; 40: 36-40. Buka okungaqondakali.
203. IHooper CA, uHaney BB, itshe HH. Ukopha emathunjini ngenxa yokushoda kukavithamini K ezigulini ezikwi-cefamandole ye-parenteral. ILancet 1980; 1: 39-40. Buka okungaqondakali.
204. I-Haubenstock A, Schmidt P, Zazgornik J, Balcke P, Kopsa H. Hypoprothrombobinaemic ukopha okuhambisana ne-ceftriaxone. ILancet 1983; 1: 1215-6. Buka okungaqondakali.
205. UDowd P, uZheng ZB. Kumshini wesenzo sokuqeda i-vitamin E quinone. I-Proc Natl Acad Sci U S A 1995; 92: 8171-5. Buka okungaqondakali.
206. UBolton-Smith C, Intengo RJ, uFenton ST, et al. Ukuhlanganiswa kwesizindalwazi se-UK sesikhashana se-phylloquinone (vitamin K1) okuqukethwe kokudla. UBr J Nutr 2000; 83: 389-99. Buka okungaqondakali.
207. UDavies VA, uRothberg AD, u-Argent AC, u-Atkinson PM, uStaub H, uPienaar NL. Isimo se-precursor prothrombin ezigulini ezithola izidakamizwa ze-anticonvulsant. ILancet 1985; 1: 126-8. Buka okungaqondakali.
208. UDavidson MH, uHauptman J, uDiGirolamo M, et al. Ukulawulwa kwesisindo nokuncipha kwengozi ezifundweni ezikhuluphele eziphathwe iminyaka engu-2 nge-orlistat. I-JAMA 1999; 281: 235-42. Buka okungaqondakali.
209. Schade RWB, van’t Laar A, Majoor CLH, Jansen AP. Ucwaningo lokuqhathanisa lwemiphumela ye-cholestyramine ne-neomycin ekwelapheni uhlobo II lwe-hyperlipoproteinemia. I-Acta Med Scand 1976; 199: 175-80 .. Buka okungaqondakali.
210. UBendich A, uLangseth L. Ukuphepha kukavithamini A. Am J Clin Nutr 1989; 49: 358-71 .. Buka okungaqondakali.
211. UMcDuffie JR, uCalis KA, uBooth SL, et al. Imiphumela ye-orlistat kumavithamini ancibilika okunamafutha kwintsha ekhuluphele. I-Pharmacotherapy 2002; 22: 814-22 .. Buka okungaqondakali.
212. IGoldin BR, iLichtenstein AH, iGorbach SL. Izindima zokudla okunempilo kanye ne-metabolic yezimbali zamathumbu. Ku: Shils ME, Olson JA, Shike M, eds. Nutrition Yesimanje Kwezempilo Nezifo, umhlaka 8. IMalvern, PA: Lea & Febiger, 1994.
213. IBhodi Yezokudla Nezokudla, Isikhungo Sezokwelapha. Ukufakwa Kwezikhombo Zezokudla ku-Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, neZinc. Washington, DC: National Academy Press, 2002. Itholakala ku: www.nap.edu/books/0309072794/html/.
214. UJamal SA, uBrowner WS, uBauer DC, uCummings SR. Ukusetshenziswa kweWarfarin kanye nobungozi be-osteoporosis kwabesifazane asebekhulile. Ukufundwa Kweqembu Locwaningo Lwama-Fractures Osteoporotic. U-Ann Intern Med 1998; 128: 829-832. Buka okungaqondakali.
215. Umgundi uMJ. Izindima zamavithamini D no-K empilweni yamathambo nokuvinjelwa kwamathambo. I-Proc Nutr Sci 1997; 56: 915-37. Buka okungaqondakali.
216. UTamatani M, Morimoto S, Nakajima M, et al. Kwehliswe amazinga ajikelezayo kavithamini K no-25-hydroxyvitamin D emadodeni amadala asebenzisa i-osteopenic. IMetabolism 1998; 47: 195-9. Buka okungaqondakali.
217. U-Weber P. Ukuphathwa kwe-osteoporosis: ingabe kukhona iqhaza ku-vitamin K? I-Int J Vitam Nutr Res 1997; 67: 350-356. Buka okungaqondakali.
218. Intengo PA. Ukudla okunomsoco we-Vitamin K kanye ne-postmenopausal osteoporosis. UJ Clin Invest 1993; 91: 1268. Buka okungaqondakali.
219. U-Yonemura K, uKimura M, uMiyaji T, uHishida A. Umphumela wesikhashana wokuphathwa kwe-vitamin K ekulahlekelweni kwe-prednisolone okubangelwa ukulahleka kwesisindo samathambo ezigulini ezine-glomerulonephritis engapheli. Izicubu zeCalcif Int 2000; 66: 123-8. Buka okungaqondakali.
220. Knapen MH, Hamulyak K, Vermeer C. Umphumela we-vitamin K supplementation ekusakazeni i-osteocalcin (bone Gla protein) kanye ne-urinary calcium excretion. U-Ann Intern Med 1989; 111: 1001-5. Buka okungaqondakali.
221. UDouglas AS, uRobins SP, uHutchison JD, et al. I-Carboxylation ye-osteocalcin kwabesifazane be-post-menopausal osteoporotic abalandela i-vitamin K ne-D supplementation. Ithambo 1995; 17: 15-20. Buka okungaqondakali.
222. IBooth SL, iTucker KL, Chen H, et al. Ukufakwa kwamavithamini K okudla kuhlotshaniswa nokuqhekeka kwesinqe kepha hhayi nobuningi bamathambo emadodeni nakwabesifazane asebekhulile. NginguJ J Clin Nutr 2000; 71: 1201-8. Buka okungaqondakali.
223. UHeck AM, uDeWitt BA, uLukes AL. Ukusebenzisana okungenzeka phakathi kwezinye izindlela zokwelashwa kanye ne-warfarin. NginguJ J Health Syst Pharm 2000; 57: 1221-7. Buka okungaqondakali.
224. I-Becker GL. Icala elibhekene no-oyela wamaminerali. NginguJ J Digestive Dis 1952; 19: 344-8. Buka okungaqondakali.
225. USchwarz KB, uGoldstein PD, uWitztum JL, et al. Ukugxila kwamavithamini ancibilika emzimbeni ezinganeni ezine-hypercholestrolemic eziphathwe nge-colestipol. Izifo zezingane 1980; 65: 243-50. Buka okungaqondakali.
226. IKnodel LC, uTalbert RL. Imiphumela emibi yezidakamizwa ze-hypolipidaemic. IMed Toxicol 1987; 2: 10-32. Buka okungaqondakali.
227. INtshonalanga RJ, uLloyd JK. Umphumela we-cholestyramine ekumungeni kwamathumbu. Amathambo 1975; 16: 93-8. Buka okungaqondakali.
228. UConly JM, uStein K, uWorobetz L, uRutledge-Harding S. Umnikelo kavithamini K2 (menaquinones) okhiqizwe yi-microflora yamathumbu kuzidingo zomsoco zabantu ku-vitamin K. Am J Gastroenterol 1994; 89: 915-23. Buka okungaqondakali.
229. IHill MJ. Izimbali zamathumbu kanye ne-vitamin endogenous synthesis. I-Eur J Cancer Prev 1997; 6: S43-5. Buka okungaqondakali.
230. I-Spigset O. Umphumela owehlisiwe we-warfarin obangelwe yi-ubidecarenone. ILancet 1994; 334: 1372-3. Buka okungaqondakali.
231. Roche, Inc. Xenical package insert. INutley, NJ. Meyi 1999.
232. UFeskanich D, Weber P, Willett WC, et al. Ukuvithiza i-Vitamin K kanye ne-hip fractures kwabesifazane: isifundo esizoba khona. Ngingu-J J Nutriti 1999; 69: 74-9. Buka okungaqondakali.
233. UHardman JG, uLimbird LL, uMolinoff PB, ama-eds. UGoodman noGillman’s The Pharmacological Basis of Therapeutics, umhla ka-9. ENew York, NY: McGraw-Hill, 1996.
234. I-DS encane. Imiphumela Yezidakamizwa Ekuvivinyweni Kwelabhoratri Yomtholampilo 4th ed. IWashington: I-AACC Press, 1995.
235. UCorrigan JJ Jr, uMarcus FI. I-Coagulopathy ehlotshaniswa nokungeniswa kukavithamini E. I-JAMA 1974; 230: 1300-1. Buka okungaqondakali.
236. UShearer MJ, uBach A, uKohlmeier M. Chemistry, imithombo yokudla okunempilo, ukusatshalaliswa kwezicubu kanye ne-metabolism ka-vitamin K ngokubhekisele ngokukhethekile empilweni yethambo. UJ Nutriti 1996; 126: 1181S-6S. Buka okungaqondakali.
237. UCanai T, Takagi T, Masuhiro K, et al. Izinga le-Serum vitamin K nobuningi bamathambo kwabesifazane abangemva kokuya esikhathini. I-Int J Gynaecol Isithiyo 1997; 56: 25-30. Buka okungaqondakali.
238. UHodges SJ, Akesson K, Vergnaud P, et al. Amazinga ajikelezayo wamavithamini K1 no-K2 anciphile kwabesifazane asebekhulile abanokuphuka kwe-hip. UJ Bone Miner Res 1993; 8: 1241-5. Buka okungaqondakali.
239. UHart JP, uShearer MJ, uKlenerman L, et al. Ukutholwa kwe-Electrochemical yamazinga wokujikeleza acindezelekile wevithamini K1 e-osteoporosis. UJ Clin Endocrinol Metab 1985; 60: 1268-9. Buka okungaqondakali.
240. UBitensky L, uHart JP, uCatterall A, et al. Ukujikeleza amazinga kavithamini K ezigulini ezinokuphuka. UJ Bone Joint Surg Br 1988; 70: 663-4. Buka okungaqondakali.
241. UNagasawa Y, Fujii M, Kajimoto Y, et al. I-Vitamin K2 kanye ne-serum cholesterol ezigulini eziqhubekayo ze-peritoneal dialysis eqhubekayo. ILancet 1998; 351: 724. Buka okungaqondakali.
242. Iwamoto I, Kosha S, Noguchi S, et al. Ucwaningo lwe-longitudinal lomphumela wevithamini K2 kumathambo amaminerali kubantu besifazane be-postmenopausal isifundo sokuqhathanisa ne-vitamin D3 kanye ne-estrogen-progestin therapy. UMatritas 1999; 31: 161-4. Buka okungaqondakali.
243. UVermeer C, uShurhurgers LJ. Ukubuyekezwa okuphelele kwabaphikisi bakavithamini K novithamini K. IHematol Oncol Clin North Am 2000; 14: 339-53. Buka okungaqondakali.
244. UVermeer C, uGijsbers BL, uCraciun AM, et al. Imiphumela kavithamini K kusisindo samathambo nethambo metabolism. UJ Nutriti 1996; 126: 1187S-91S. Buka okungaqondakali.
245. U-Olson RE. Ukudla kwamathambo kanye novithamini K. Ngingu-J J Nutriti 2000; 71: 1031-2. Buka okungaqondakali.
246. UShiraki M, Shiraki Y, Aoki C, Miura M. Vitamin K2 (menatetrenone) uvimbela ngempumelelo ukuqhekeka futhi aqinise amandla amaminerali amathambo e-osteoporosis. UJ Bone Miner Res 2000; 15: 515-21. Buka okungaqondakali.
247. UJie KG, uBots ML, uVermeer C, et al. Isimo se-Vitamin K nobukhulu bamathambo kwabesifazane abane-atherosclerosis engaphandle kwe-aortic: isifundo esenziwe ngabantu. Izicubu zeCalcif Int 1996; 59: 352-6. Buka okungaqondakali.
248. UCaraballo PJ, Heit JA, Atkinson EJ, et al. Ukusetshenziswa kwesikhathi eside kwama-anticoagulants omlomo kanye nengozi yokwephuka. I-Arch Intern Med 1999; 159: 1750-6. Buka okungaqondakali.
249. Matsunaga S, Ito H, Sakou T. Umphumela we-vitamin K no-D ukwengezelwa ekulahlekelweni kwethambo okubangelwa i-ovariectomy. Izicubu zeCalcif Int 1999; 65: 285-9. Buka okungaqondakali.
250. U-Ellenhorn MJ, et al. I-Ellenhorn's Medical Toxicology: Ukuxilongwa Nokulashwa Kobuthi Bomuntu. Okwesibili. IBaltimore, MD: Williams & Wilkins, 1997.
251. UMcEvoy GK, umhleli. Imininingwane Yezidakamizwa ze-AHFS. I-Bethesda, MD: I-American Society of Health-System Pharmacists, ngo-1998.

Kugcine ukubuyekezwa - 10/26/2020